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PREFACE 
The idea that iodine and thyroid function were somehow interrelated, dates 
from the beginning of the nineteenth century. After the discovery of iodine 
as a new element in 1813 (Courtois et al, 1813), and the demonstration of 
its presence in common sponge in 1819, Coindet, a physician in Geneva, 
suspected that the ancient remedy for goitre: burnt sponge, might contain iodine 
and he decided to start treatment of his goitrous patients with iodine (Coindet, 
1820). Initially successful and taken up with enthousiasm, this therapy was 
gradually abandoned by the subsequent awareness of the hazards of overdosage. 
It was not until 1896 that Baumann could demonstrate iodine in thyroid glands 
(Baumann, 1896). He named his product "iodothyrin" which was soon shown 
to possess a similar activity compared to whole thyroid when administered 
to hypothyroid patients. In the years thereafter, Baumann and coworkers could 
demonstrate a correlation between iodine content of iodothyrin and its activity, 
while the iodine-free fraction of the thyroid extracts was devoid of biological 
activity (Baumann and Roos, 1896). Furthermore, thyroid glands of goitrous 
patients were shown to contain less iodine than those of non-goitrous patients 
(Baumann, 1896a). From that time it became generally accepted that iodine 
was an essential constituent and product of normally functioning thyroid glands. 
Further attempts to analyze and isolate the active compound in iodothyrin 
were unsuccessful until Kendall, in 1914, succeeded in preparing a purer 
crystalline substance, which he named "iodin-A" (Kendall, 1915). He later 
changed this name in "thyroxine" and also proposed a structure formula which 
best fitted his analytical data (Kendall, 1917). Although incorrect, it is interesting 
to note that this formula includes three iodine atoms. In 1926, Harrington 
definitely established the chemical structure of thyroxine and subsequently 
synthesized it as 3,3',5,5'-tetraiodothyronine (hence the abbreviation: T4) 
(Harrington, 1926). 
In the years thereafter, however, it was increasingly felt that the physiological 
activity of thyroid material could not be entirely accounted for by its thyroxine 
content and as early as 1929 Kendall suggested that "thyroxine must represent 
an intermediate form in the elaboration of the physiologically active compound 
which is probably derived directly from thyroxine" (see for a historical review 
Pitt- Rivers, 1978). A major breakthrough in the history of thyroid research 
came with the discovery of 3,3' ,5-triiodothyronine (T3) by Gross and Pitt-Rivers 
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in 1952 (Gross and Pitt-Rivers). They could demonstrate T3 in thyroids and 
plasma of 1311 treated rats, beef thyroids and plasma of 1311-treated patients. 
At approximately the same time, Roche and coworkers also succeeded in 
synthesizing T3 and demonstrating its presence in thyroid glands of rats given 
1311 (Roche et al, 1952, 1952a). Synthetic L-T3 was shown to possess a biological 
potency of about three times that of thyroxine (Gross and Pitt-Rivers, 1952a). 
Furthermore, the period between the time of administration and the peak 
metabolic effect was much shorter in the case of T3 than in that of T4. These 
findings and the above mentioned suggestion of Kendall, in addition to the 
finding of in vivo conversion of T4 to T3 by Pitt- Rivers et al, made them 
to suggest that "triiodothyronine is the peripheral hormone and that thyroxine 
is its precursor" (Gross and Pitt-Rivers, 1953). This statement was already 
made before they showed in vivo T4 to T3 conversion. Some in vitro studies 
also showed conversion of T4 to T3 in peripheral tissues (Albright et al, 1954), 
but, because other studies (Lassiter and Stanbury, 1958) did not support these 
observations, the subject remained dormant until 1970, when Braverman et 
al were able to demonstrate formation of T 3 from T 4 in athyreotic human 
subjects in whom substitution therapy with L- thyroxine was the only possible 
source of T 3· From that time the research of the peripheral metabolism of 
thyroid hormones has explosively expanded. 
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CHAPTER 1 
Introduction 
The principle secretory products of the thyroid gland are: thyroxine (3,3',5,5'-
tetraiodothyronine) and 3,3',5-triiodothyronine, T3. In normal conditions, with 
sufficient iodine intake, these hormones are produced in the thyroid in a molar 
ratio of about 20:1 (Nagataki et al, 1972; Chopra et al, 1973; Larsen et al, 
1973), which differs considerably from their blood production rates of about 
3:1 (Chopra, 1976), suggesting an extrathyroidal source for circulating T3. In 
this respect, it was interesting to observe normal serum T3levels in L- thyroxine 
substituted athyreotic human subjects (Braverman et al, 1970). The only possible 
source of this T3 was orally taken thyroxine, so the conclusion that T4 was 
converted peripherally to T 3 was inevitable. That T 4 to T 3 conversion does 
occur in vivo has been repeatedly demonstrated in subsequent years (Sterling 
et al, 1970, Pittman et al, 1971, Surks et al, 1973). It is now widely accepted, 
that the major part of circulating T3 is derived from extrathyroidal T4 
deiodination (Chopra et al, 1978). The same applies, even stronger, for 3,3',5'-
triidothyronine, reverse T3 (rT3) (see later sections) (Chopra et al, 1978). Much 
work has been done to reveal the specific tissues and localization in which 
T4 conversion takes place. Until recently, in vivo investigations have not yielded 
clear indications as to the site of thyroid hormone deiodination. The subject 
became even more complex when it was demonstrated that reproducible, 
predictable and reversible changes in T4 deiodination, reflected by changes 
in serum levels of T3 and rT3, could be induced by several procedures. Before 
discussing the possible mechanisms by which these changes in serum levels 
of iodothyronines, which are known as the low T 3 syndrome, could take place, 
a summary of some aspects of peripheral thyroid hormone metabolism is given. 
This summary serves as a background and theoretical basis for the questions 
which resulted in the various investigations reported in this thesis. 
Some aspects of peripheral thyroid hormone metabolism 
Thyroxine, which is exclusively synthesized in the thyroid gland, is peripherally 
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metabolized via several pathways: a) deiodination, b) oxidative deamination, 
c) conjugation and d) etherbond cleavage (see figure 1). Deiodination is 
quantitatively the most important pathway, accounting for up to 80% of T4 
turnover (Chopra, 1976, Gavin et al, 1977; Engler and Burger, 1984). T4 is 
also lost in bile and urine as the pure compound and T 4-conjugates, mainly 
in the form of glucuronyl- and sulfoconjugates. The amount of T 4 lost via 
these routes has been estimated at about 15% of the total T 4 production (Chopra, 
1976; Chopra et al, 1978; Oddie et al, 1964). In addition, a small amount 
of T4 is metabolized via oxidative deamination and decarboxylation of the 
alanine side chain to yield 3,3',5,5'-tetraiodothyroacetic acid (Tetrac) which 
can be further metabolized primarily by deiodination and to a lesser extent 
by conjugation (Flock et al, 1962; Green and Ingbar, 1961). Etherbond cleavage 
is considered to constitute a minor metabolic pathway of thyroid hormones. 
For a schematic representation, see fig. 2 and 3. In the following we will be 
predominantly concerned with the deiodinative pathway. 
In assessing the thyroidal contribution to the total production of T 3, it has 
been assumed that the secretion of T 4 and T 3 by the thyroid, is proportional 
to their content in thyroglobulin (Chopra et al, 1978). Although a preferential 
secretion of T3 in the rat (Haibach 1971) and rT3 in the dog (Laurberg, 1978) 
was suggested, other studies (Abrams and Larsen, 1973) showed a good 
agreement between the T 3/T 4 ratio in thyroidal secretory products and in 
thyroglobulin. Because T4 is exclusively secreted by the thyroid, the thyroidal 
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T3 production rate can be obtained by multiplying the T3/T4 ratio in thy-
roglobulin by the production rate of T4. The same applies for rT3. In this 
way a thyroidal contribution of 20 and 6 percent in the total daily blood 
production rate of T3 and rT3, respectively, has been accepted (table 1). It 
can therefore be stated, that the production of active thyroid hormone takes 
place mainly outside the thyroid gland (Visser, 1980). Apart from the question, 
where this production takes place, it was soon recognized that in serum, T3 
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Table 1. Contributions of thyroidal secretion and peripheral production 
to total production rates of T4, T3 and reverse T3 
lodothyronine Total production Thyroidal secretion (%) Peripheral 
(nmol/day/70 kg) production 
T4 115 115 ( 1 00) 
T3 45 9 (20) 36 (80) 
rT3 30 2 (6) 28 (94) 
Data from Chopra 1976 and Chopra eta\, 1978 
and rT3 are not always present in a fixed ratio, but that reciproke changes 
in T3 and rT3 serum concentrations, with unaltered T4 serum levels, could 
be detected in several conditions (vide infra). Reverse T3 was identified in 1956 
by Roche et al, both in thyroids and serum of rats. In 1974, it could be 
demonstrated in human serum (Chopra, 1974). In contrast to T3, which is 
considered as the metabolically most active iodothyronine, rT3' is currently 
regarded to be biologically inactive (Jorgensen, 1976). 
Thus it was increasingly recognized that a peripherally localized regulatory 
system is present, by which T 4 which is also considered to possess little, if 
any, biological activity (see for a discussion on this subject G. Morreale de 
Escobar et al, 1981; M. Andreoli, 1981), is conv~rted to the biologically active 
hormone: T3 and its inactive analogue reverse T3. · 
In the last decade much progress has been made in understanding the 
mechanisms by which these changes in serum T3 and rT3 take place. Firstly, 
changes in iodothyronines associated with caloric deprivation will be considered. 
Changes in serum iodothyronines during caloric deprivation and dietary 
manipulations 
The interest in dietary induced changes in serum iodothyronines actually began 
with the intriguing observation (Portnay et al, 1974) of a decreased serum 
T3 level in man during starvation. After a reliable specific radioimmuno-assay 
for rT 3 had become available (Chopra, 197 4 ), this observation was soon extended 
by the demonstration of a concomitant rise in rT 3 during caloric restriction 
(Vagenakis et al; 1975; Spaulding et al, 1976). Interestingly, total serum T4 
concentrations did not change, as had been shown before (Schatz et al, 1967; 
Verdy, 1968). Similar effects were observed in fasted non-obese L-thyroxine 
substituted hypothyroid patients ( Croxson et al, 1977) and fasted obese euthyroid 
patients on a suppressive (250 ug) L-thyroxine dose (Vagenakis et al, 1975). 
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Since then, these observations have repeatedly been confirmed by others (Carlson 
et al, 1977; Azizi, 1978; Burman et al, 1979; Moreira-Andres et al, 1980), not 
only in starvation, but also in anorexia nervosa (Moshang et al, 1975; Miyai 
et al, 1975; Croxson and Ibbertson, 1977). It ·was, however, early recognized, 
that these changes in thyroid hormones were, in addition to the amount of 
caloric intake, also related to the dietary composition. A rise in serum T3 
was demonstrated in normal subjects during overfeeding of carbohydrate, 
whereas a reduction in_ carbohydrate was associated with a decrease in serum 
T3level (Danforth et al; 1975)~ This latter observation was extended (Spaulding 
et al, 1976) by showing that feeding obese subjects a 800 kcal diet devoid 
of carbol:wdrate, resulted in a decreased serum T3, similar to total caloric 
restriction. Serum rT3 levels, however, did not alter. If the 800 kcal diet was 
composed of at least 25% of carbohydrate related calories, the serum con-
centration of neither T 3 nor rT 3 was changed. In concert with these observations 
were the findings of Azizi (1978), who showed that - after fasting- refeeding 
with a 800 kcal mixed diet (70g carbohydrate, 50g protein and 35g fat, for 
4 days) and isocaloric 100% carbohydrate diet, serum concentrations of T3 
and rT 3 returned towards normal, while a 800 kcal protein diet only restbred 
rT3 concentration. Burman et al (1979) could also demonstrate the efficacy 
of a relatively small amount (50g) of glucose (and fructose) in restoring T3 
and rT3 serum levels after a seven day period of fasting. These findings suggested 
an important role of glucose metabolism in the peripheral deiodination of thyroid 
hormones. In particular, hepatic glucose metabolism attracted attention, after 
Westgren et al (1977) observed a stimulation of peripheral T3 formation by 
oral but not by intravenous glucose administration in fasted subjects. In addition 
to this carbohydrate effect on peripheral thyroid l:,J.ormone metabolism, an active 
role of dietary fat has been suggested (Otten et al, 1980). These authors compared 
changes in iodothyronines during four diets containing 1500 kcal each, composed 
of either 100% fat, 50% fat - 50% carbohydrate, 50% fat -50% protein or 
a control, mixed diet. Changes in thyroid hormones during the all-fat diet 
were qualitatively and quantitatively similar to those seen during fasting. In 
the 50% fat - 50% carbohydrate group a decrease (24%) in serum T3 level 
was seen, while rT3 concentration raised up to 34%. A similar increase in 
rT 3 serum levels was seen in the 50% fat - 50% protein fed subjects, but in 
this group the decrease in T3 serum concentration was most pronounced. It 
was suggested that fat had a negative effect on peripheral thyroid hormone 
deiodination and this effect could (partially) be prevented by carbohydrates 
and proteins. With regard to inhibiting the suggested influence of fat, proteins, 
however, were more potent in restoring rT3 levels than T3 concentrations. This 
is supported by the above mentioned data of Azizi (1978), who observed restoring 
only rT3 levels in fasted subjects refed with 800 kcal protein-diet. 
Later studies, however, do not confirm all the above mentioned data. O'Brian 
et al (1980) observed changes in serum T3 and rT3 during severely restricted 
diets (200-600 kcal per day) similar to those in total starvation, irrespective 
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if calories were administered entirely as carbohydrate or protein. Also, Serog 
et al (1982) found that adding 110 grams of carbohydrate to a 1400 kcal/ 
day diet, did not prevent the expected diet induced changes in T3 and rT3. 
Bogardus et al (1982) noted that adding 75g of carbohydrate to a 830 kcal/ 
day diet containing no carbohydrate, for 6 weeks, did not prevent the decrease 
in serum T3, but did prevent the increase in rT3. 
T4, T3 and rT3 are tightly, but reversibly bound to serum carrier proteins, 
which in man include thyroxine binding globulin (TBG), thyroxine binding 
prealbumin (TBPA) and albumin. TBG has the highest affinity, but also the 
lowest capacity, and binds about 75% of.all circulating T4, T3 and rT3. TBPA 
has a lower affinity, but a larger capacity and binds 20% of T 4 and less than 
5% of T3. Albumin has the lowest affinity but highest capacity, binding 10% 
of T 4 and 20% of T 3. A small fraction of circulating thyroid hormone is non-
protein-bound, the so called "free hormone". The free fractions for these 
hormones are: T4: 0.02%; T3: 0.3%; rT3: 0.25%. The absolute free hormone 
concentration is obtained by multiplying total hormone levels by the free 
fractions. The free hormone is in equilibrium with the protein- bound fraction 
and in euthyroid conditions, the free hormone concentration is unchanged, 
despite significant changes in total hormone levels due to changes in capacity 
of binding proteins, for instance a rise in TBG in pregnancy. Therefore, changes 
in serum iodothyronines in certain conditions should also be regarded with 
respect to a possible change in serum binding proteins. Proteincaloric mal-
nutrition was found to induce a decrease in TBPA and albumin, without a 
change in TBG (Chopra and Smith, 1975). Moreira-Andres et al (1980) showed 
a markedly decrease in TBPA (26%) and a small decrease in TBG (8.5%) 
without changes in albumin, during a two week period of caloric depriv~tion 
(500 kcal; 27g fat; 36g carbohydrate; 39g protein). However, the observed 
changes in T 3 and rT 3 could not in anyway be accounted for by these changes 
in binding proteins. Bogardus et al (1982) reached the same conclusion. The 
effect of caloric intake and carbohydrate on serum carrier proteins of thyroid 
hormones remains a matter of interest. 
Welle et al ( 1983) found an increase in TBG and TBPA with markedly elevated 
serum T3 levels during carbohydrate overfeeding. Surprisingly, free T3 levels 
were also increased. The effect of carbohydrate on thyroid hormone binding 
proteins may also be independant of caloric intake, since TBPA is decreased 
in normal subjects when fed eucaloric carbohydrate restricted diets (Kelleher 
et al, 1983). 
The possible existence of a circulating substance, inhibiting binding of thyroid 
hormone to its serum carrier proteins, thereby influencing the serum iodo-
thyronine levels, will be discussed later. 
In conclusion: caloric deprivation has been shown to induce changes in serum 
levels of thyroid hormones. These alterations are not solely dependent on the 
amount of caloric intake, but are also related to the composition of the diet. 
Carbohydrates seem to play a central role (not confirmed in all studies), but 
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a more active role of fat has also been suggested. The changes in serum 
concentrations of TBG, TBPA and albumin, observed during caloric mani-
pulation, do not appear to account for the altered serum levels of T3 and 
rT3. As yet, the mechanism by which these dietary manoeuvres induce the 
above cited changes in serum iodothyronines, remains to be elucidated and 
will be discussed in the following sections. 
Kinetics of serum iodothyronines during caloric deprivation. 
An other approach to reveal the mechanism by which changes in serum 
iodothyronines during starvation take place, is to assess the kinetics of these 
hormones. Turnover kinetic studies require the intravenous administration of 
isotope-labeled hormone. Iodine isotopes are usually used in thyroid hormone 
tracer kinetic studies. Stable iodine is orally administered in order to prevent 
thyroidal uptake and recirculation of radioiodine, derived from the breakdown 
of hormone tracers. In the single compartmental model (SCM), a single (pulse) 
injection of radioactive iodothyronine is given intravenously. Serum tracer 
concentration is semilogarithmically plotted against time. The terminal slope 
of the plasma disappearance curve is linear, indicating that equilibrium has 
been reached between the plasma compartment and the rest of the body. By 
extrapolating this terminal part of the curve, the time-zero intercept represents 
the plasma tracer concentration if equilibrium existed already at that time. 
The volume of distribution (DV), which is actually a virtual volume and is 
expressed in liters plasma, can be obtained by dividing the injected dose by 
this zero time tracer concentration. The slope of the linear part of the curve 
represents the fractional catabolic rate (k), which can be calculated as k= 0.693/ 
Tl/2 . The metabolic clearance rate (MCR) can be obtained by multiplying 
k and DV and refers to the volume of plasma from which a iodothyronine 
is cleared irreversibly per unit of time. In a steady state condition disposal 
of a iodothyronine equals its production rate (PR), hence PR=MCR x plasma 
hormone concentration. The total amount of hormone in the body (pool) can 
be calculated as: pool = DVx plasma hormone concentration. 
If during the initial phase of distribution after the pulse injected tracer, 
significant degradation of a iodothyronine occurs, equilibrium between plasma 
and the rest of the body will be reached at a lower serum tracer concentration, 
with a subsequently lower extrapolated time zero tracer concentration, resulting 
in a higher DV and therefore overestimation of the MCR. To avoid these 
pitfalls, other approaches have been used like the constant infusion technique 
(Cavalieri et al, 1971), three compartmental model (Inada et al, 1975) and 
the currently more generally used non-compartmental model (NCM). This model 
considers a central compartment which is defined as the fast initial distribution 
space of iodothyronine and includes plasma pool as well as a number of other 
extravascular pools (compartments), reversibly exchanging the iodothyronine 
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with the central compartment. The term "non-compartmental" is used, because 
no definite compartmental localization of iodothyronine is assumed. The MCR 
is obtained by dividing the dose of injected labeled iodothyronine by the 
integrated plasma concentration determined by calculating the area under the 
plasma disappearance curve of the injected labeled hormone. (For mathematical 
background see Oppenheimer et al, 1975a, b; Gavin et al, 1977; Bianchi et 
al, 1978). This method also yields in addition to a MCR, a fractional turnover 
rate and distribution volume . 
. For T3 it has been shown (Oppenheimer, 1975 a, b) that single compartmental 
analysis overestimates the distribution volume and MCR of T 3 by 94% and 
30%, respectively. These differences are due to the relatively rapid turnover 
of T3, in contrast to T4, for which no important differences between SCM 
and NCM were found, most probably due to its much more slower turnover 
rate. 
Using such methods of kinetic analysis, three studies, which can be considered 
as classic, have assessed the kinetic parameters ofT 4, T 3 and rT 3 during caloric 
deprivation. In the earliest study (Vagenakis et al, 1977), nine euthyroid obese 
subjects were studied before and after three weeks of total caloric deprivation. 
The MCR and serum concentration of T 4 did not change, resulting in an 
unaltered PR. In contrast, T 3 PR decreased markedly, concluded from a 
decreased serum T 3 concentration and unchanged MCR. The decrease in T 3 
PR was approximately 70%. In this study no rT 3 metabolism was investigated. 
Therefore, the same group (Eisenstein et al, 1978) assessed the kinetic parameters 
of this iodothyronine in four additional obese euthyroid patients. It should 
be noted that this kinetic study started on the sixth day of the fasting period, 
in contrast to day 21 in the former study. A 69% increase was found in serum 
rT3 levels, while rT3 MCR diminished from 96 to 68 liters/day /70 kg, resulting 
in a slight increase in the rT 3 PR. From these two studies it was concluded 
that the major cause of the lowered serum T 3levels during fasting was a decreased 
production rate, while the rise in rT 3 concentration resulted from a decreased 
metabolic clearance rate. In a third investigation Suda et al (1978) studied 
the plasma peripheral kinetics ofT 4, T 3 and rT 3 in seven obese fasting subjects 
and compared them to normal-weight persons. All volunteers were placed on 
a normal L-thyroxine substitution dose starting three weeks before the study. 
Kinetics ofT 4 and rT 3 were started on day 3 of the fasting period, while labeled 
T3 was injected on day 6. T4 MCR was slightly lower in the fasted group 
(25%), as was the T4 disposal rate (19%). Because all persons were on L-
T4 replacement, a decreased plasma disposal rate (=plasma production or 
appearance rate) is not to be expected, unless, as the authors suggested, a 
decrease in gastrointestinal absorption of L-T 4 is present. A possible explanation 
for a lowered T4 MCR is a more intricate subject and will be discussed later. 
In contrast to the findings of Vagenakis (vide supra) T3 MCR was reduced 
by 20%. Because serum T3 concentration decreased much more, T3 disposal 
rate was lowered by 59% compared to the fed group. Reverse T3 MCR was 
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48% lower, but because of a 140% increase in plasma rT3 concentration, the 
disposal rate was unchanged or slightly increased. 
In conclusion: during caloric deprivation, decreased serum T 3 levels mainly 
result from decreased T3 production, while increased rT3 concentrations are 
due to a diminished rT3 MCR. No major changes are observed in T3 MCR 
and rT 3 PR. It should, however, be mentioned, that rT 3 tracer kinetic studies 
were all performed in the initial period of fasting, while it became apparent 
that after an initial rise in serum rT3 (already demonstrable within 24h of 
starvation and which rise is maximal after one week and a half), hormone 
concentration subsequently gradually returns towards its prefast value (Visser 
et al, 1978; Carlson et al, 1977). This is in contrast to the sustained reduction 
of serum T3 (Visser et al, 1978) although a concomitant rise in serum T3 has 
also been reported (Suda et al, 1978; Carlson et al, 1977). As yet, no data 
are available as to the kinetic parameters of rT 3 after prolonged fasting. 
Theoretically, a gradual decrease in rT3 serum levels could be a reflection of 
an increase in MCR as well as a decrease in PR. Vagenakis et al (1977) performed, 
as noted above, T 3 kinetic studies after 21 days of fasting and found an unchanged 
T3 MCR with a decreased T3 PR, in concert with kinetic data obtained during 
early fasting periods. 
Enzymic activities in deiodination of iodothyronines 
When it became evident that the deiodinative conversion of T4 to T3 and rT3, 
was not a random process as had been suggested by Surks and Oppenheimer 
(1971), more interest arose in the biochemical background of this deiodinating 
process. It was only in 1975 that the enzymic nature of this reaction was 
established in rat liver homogenates (Hesh et al, 1975; Visser et al, 1975). 
In subsequent subcellular fractionation studies, most authors reported on a 
microsomal localization of the deiodinase activity in the liver (Visser et al, 
1976; Fekkes et al, 1979; Auf dem Brinke et al, 1979; Saito et al, 1980) while 
others showed that the kidney enzyme is associated with the plasma membrane 
(Chiraseveenuprapund et al, 1978; Leonard and Rosenberg, 1978). (See for 
an extensive review on this subject Fekkes, 1982, thesis). Later investigations 
provided insight into the mechanism of enzymic deiodination and the way 
by which PTU inhibited this reaction (Leonard and Rosenberg, 1978 a; Visser, 
1979; Visser and Van Overmeeren, 1979, 1981). In these investigations, it could 
be assessed that the proposed ping-pong mechanism (Visser, 1979) for thyroid 
hormone outer ring deiodination was correct (Visser and Van Overmeeren, 
1981). It was also shown that thiol groups were essential for this enzyme activity 
as endogenous cofactor (Visser et al, 1976). 
Originally, glutathione was advocated as the principle endogenous cofactor, 
because 5' -deiodinase activity changed in proportion to hepatic glutathione 
or non-protein sulfhydryl concentration in fasting (Visser et al, 1976; Kaplan, 
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1979; Balsam and Ingbar, 1979). However, a dissociation between hepatic 
reduced glutathione content and 5'- deiodinase activity in liver homogenates 
and cultured rat hepatocytes was subsequently shown (Gavin et al, 1981; Sato 
and Robbins, 1981). As yet, the nature of the endogenous cofactor for 5'-
deiodinase activity remains a matter of investigation, but it still seems likely 
that hepatic reduced sulfhydryl-groups are somehow related to the observed 
cytosolic defect in fasting, leading to a decreased 5'-deiodinase activity. Perhaps 
not simply through the reduced glutathione concentration per se, but rather 
a change in the ratio reduced versus oxidized gluthatione. In this respect, the 
naturally occuring dithiol: dihydrolipoamide, has been suggested to play a role 
as a thiol cofactor in enzymic outer ring deiodination of T4 and rT3 (Goswani 
and Rosenberg, 1983; Sawada et al, 1985). Monodeiodinating activities have 
been observed in many animal tissues such as liver (vide supra), kidney (Chopra 
et al, 1978a), skeletal muscle (Chopra, 1977), heart (Naumann et al, 1980), 
pituitary (Kaplan, 1980), cerebral cortex and cerebellum (Kaplan and Yaskoski, 
1980) and the thyroid itself (Erickson et al, 1981). Similar activity has been 
found in tissues of human origin as kidney, liver, heart, muscle, fibroblasts, 
polymorphonuclear leukocytes, lymphocytes, placenta and thyroid (Albright 
and Larson, 1959; Refetoff et al, 1972; Sterling et al, 1973; Woeber and Maddux, 
1978, Kvetny, 1978; Roti et al, 1981; Ishii et al, 1982; Visser et al, 1983). It 
turned out that of these tissues, liver and kidney showed the greatest deiodinative 
activity. Initially, much of the attention was focussed on the liver and kidney, 
with respect to elucidate the mechanism of the alteration in iodothyronine 
serum levels during e.g. starvation. In addition to their high deiodinative activity 
in vitro, also high levels of radioactivity were noted in hepatic and renal regions 
during the first hours of injection of labeled thyroxine (Cavalieri et al, 1966). 
Furthermore, it became apparant that approximately one third of the total 
T4 pool is located in the liver (Hennemann, 1981). 
In 1978, a reduced 5'-deiodinase activity could be demonstrated in liver 
homogenates of fasted rats (Balsam and Ingbar, 1978; Kaplan and Utiger, 
1978). Subsequent studies revealed that this reduction in 5'- deiodinase activity 
(5'-D) was due to a reduced apparent Vmax in the microsomal fraction in 
addition to a lowered capacity of the cytosol to support deiodination by the 
particulate fraction (Kaplan, 1979; Balsam et al, 1981). This lowered apparent 
Vmax, presumably reflecting a decreased amount of enzyme, could partially 
be normalized by T4 replacement to fasting rats (which become hypothyroid 
during fasting) without changing the apparent Km, provided that thiol reductants 
were supplemented (Balsam et al, 1981; Gavin et al, 1981). These results indicate 
that these changes in 5'-D in the rat result from tissue hypothyroidism, although 
a reduced cytosolic factor could also contribute to this effect, since T 4 and 
T 3 replacement of fasting rats do not fully normalize 5'D (Kaplan, 1979). Protein 
feeding ofT 4 substituted rats seems to increase the sulfhydryl cofactor, whereas 
glucose feeding increases the hepatic content of active enzyme (Gavin et al, 
1981 ). 
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Evidence for transmembraneous transport of iodothyronines 
Based on investigations as discussed above, it was until recently generally held, 
that a decrease in 5'-D activity in the liver (and possibly also in other organs 
as well) could explain the changes in iodothyronine serum concentrations during 
caloric deprivation: a lowered serum T 3 level resulted from a decreased T 4 
5' -deiodination, while the concomitant rise in serum rT 3 concentration was 
secondary to the same mechanism. However, as early as 1979, this mechanism 
was challenged as the sole cause for the induction of alteration in serum thyroid 
hormones during starvation (Jennings et al, 1979). Jennings and coworkers 
perfused livers of 3 days fasted rats with T4 and observed a decreased hepatic 
T4 uptake. The rate of T4 to T3 conversion, however, did not change during 
fasting. When livers were perfused similarly in the presence of PTU, no change 
in T4 uptake was seen, but T4 to T3 conversion decreased due to inhibition 
of 5'D in the perfused rat liver. These results indicated that the diminished 
hepatic T 3 production during fasting results from decreased uptake of T 4 by 
the liver, rather than from changes in 5'D. A probable physiologic base for 
these observations was provided by the work ofKrenning et al in our laboratory 
(Krenning et al, 1978,1979,1980,1981,1982,1983). Rao et al (1976,1981) observed 
a saturable and energy dependent T3 uptake in rat liver cell suspensions. 
Subsequently in rat hepatocytes in primary culture, Krenning et al showed 
that uptake of T4, T3 and rT3 was mediated by an active transport mechanism, 
and not, as had been suggested before (Freinkel et al, 1957; Lein and Dowben, 
1961) by passive diffusion. It appeared that T4 and rT3 enter the cell by a 
common pathway that is different from that ofT 3· In addition, these pathways 
were shown to be A TP-dependent and could be inhibited by several compounds, 
known to induce a low T3 syndrome in man such as propranolol and X-ray 
contrast agents. Propranolol also decreased cellular A TP cdntent, in contrast 
to tyropanoate, iopanoic acid and ipodate (cholecystographic agents) and 
amiodarone, that decreased hepatic cellular uptake of iodothyronines. It is 
believed that these latter agents, which show structural resemblance to thyroid 
hormones, inhibit hormonal uptake by competing with thyroid hormones for 
the uptake mechanism. Very interestingly, PTU did not influence uptake of 
iodothyronines in these hepatocytes, which is in concert whh the observatibn 
in perfused rat liver (vide supra, Jennings et al, 1979). It also appeared that 
T 3 entrance into the cell was less susceptible to A TP depletion than the uptake 
ofT4 and rT3. In addition to rat hepatocytes in primary culture, similar transport 
mechanisms for T4, T3 and rT3 have been shown in cultured human fibroblasts 
(Docter et al, 1987). These findings were extended by showing inhibition of 
iodothyronine transport into rat liver cells by a monoclonal antibody (Mol 
et al, 1986) and the demonstration that carrier-mediated transport of thyroid 
hormone into rat hepatocytes is rate limiting in total cellular uptake and 
metabolism (Hennemann et al, 1986). That changes in transport of iodothy-
ronines from plasma to the tissues, may, at least, significantly contribute to 
11 
the observed alterations in serum thyroid hormones, has been suggested in 
patients with non-thyroidal illness (N. T.l. ). In these clinically euthyroid patients, 
serum total and free T 4 concentrations may be subnormal, normal or frankly 
elevated. In addition, reduced total and free T 3 and increased total and free 
rT3 serum concentrations are observed. In many instances the type and 
magnitude of these abnormalities appear to reflect the severity of illness, as 
is demonstrated for instance in patients with myocardial infarction, in which 
an inverse relationship was shown between serum total T 4 and T 3 with infarction 
size (Smith et al, 1978). Furthermore, serum levels of rT3 are higher in more 
severely ill patients (Alexander et al, 1982). For an excellent review on this 
subject, see Engler and Burger, 1984. The relationship of the severity of non-
thyroidal illness and the direction and magnitude of the alterations in serum 
thyroid hormone levels, is complex and appears to reflect a continuum, as 
depicted in fig. 4. Table 2 summarizes some important features with regard 
to changes in thyroid hormone in these patients. In mild disease these alterations 
resemble those occuring in obese subjects during acute and chronic caloric 
deprivation (Wartofsky and Burman, 1982) and a significant role of reduced 
caloric intake in these ill patients is suggested by the observation that in severely 
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to the severity of the illness. 
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Table 2. Some important changes in thyroid function parameters and 
hormone kinetics in non-thyroidal illness 
Mild/moderately ill Severely ill 
High Total T4 State Low Total T4 State 
Serum total T4 
o/o free T4 in serum (ED) 
serum free T4 (ED) 
FT4I 
TBG 
Binding to carrier proteins 
TSH 
Response of TSH to iv TRH 
serum T3 
serum rT3 
T4 MCR 
T4 PR 
1 
N 
1 
binding capacity i 
N 
N 
J 
N 
J 
1 
Nor J 
J 
N 
hormonal binding J 
N (slight 1) 
N (slight J) 
I 
1 
1 
Nor J 
Data pooled from the literature, mainly from the work of Kaptein et al. 
ED equilibrium dialysis 
TBG thyroxine binding globulin 
FT41 free thyroxine index 
MCR metabolic clearance rate 
PR production rate 
ill patients serum levels of total T3, rT3 and T4 returned towards normal after 
receiving nutritional support (Richmand et al, 1980). 
As can be deducted from table 2 important changes in hormone binding 
occur during non-thyroidal illness. The changes in serum concentration ofTBG, 
TBPA and albumin, however, do not appear to entirely account for the 
alterations in serum concentrations of T4, T3 and rT3. This led Chopra et al 
(1979) to suggest the presence of an inhibitor in serum of patients with NTI, 
resulting in decreased binding of thyroid hormones to their carrier proteins. 
Due to its physiochemical properties, this inhibitor was thought to be an lgM-
like protein or a substance complexed with lgM. Subsequently, this inhibitor 
was shown to be a constituent of extrathyroidal tissue during NTI and it was 
hypothesized that this factor leaks out of the tissues into the plasma during 
NTI (Chopra et al, 1985). Oppenheimer and coworkers (1982) also suggested 
that in NTI substances were involved in inhibiting iodothyronine binding to 
plasma proteins. They, however, did not reach the conclusion that this factor 
was an immunoglobulin. Interestingly, serum of patients with NTI showed 
the ability of inhibiting 125I-T4 uptake by cultured rat hepatocytes, suggesting 
that this inhibitor might possess biological importance. These findings were 
extended by Chopra and coworkers (Chopra et al 1985, 1986). They showed 
a very close correlation between the thyroid hormone-binding inhibitor (THBI) 
and an inhibitor of extrathyroidal conversion of T4 to T3 (IEC) in sera of 
patients with non-thyroidal illness. Although the exact nature of THBI and 
IEC is still unclear, many arguments are in favour of a lipid, more specifically 
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fatty acids, as being both the THBI and IEC. This is the more interesting, 
since serum concentration of fatty acids increase during many circumstances 
in which a low T3 syndrome arises (Chopra et al, 1985). Fatty acids increase 
the fluidity and negative surface charges of cell membranes (Ahrens, 1981; 
Schmalzing, 1982) and it is feasible that these membrane effects interfere with 
transmembraneous transport of thyroid hormones as proposed by Krenning 
et al (vide supra) and substantiated by their recent demonstration that sera 
of patients with non-thyroidal illness and a low total serum T4, inhibit thyroid 
hormone uptake by hepatocytes · in primairy culture without a direct effect 
on deiodination (Krenning et al, 1986). 
From the work of Irvine (1974) and Irvine and Simpson-Morgan (1974) 
it is suggested that transcapillary movement of thyroid hormones occurs as 
iodothyronine-protein complex in hepatic tissues, whereas for other tissues such 
as muscle, skin and intestine, transcapillary movement of thyroid hormone 
is mainly in the non-protein bound, i.e. free, form. 
Because of the above mentioned changes (table 2) in serum carrier proteins 
of iodothyronines and the existance of a thyroid hormone binding inhibitor 
during non-thyroidal illness, determination of the MCR should also be regarded 
with respect to a changed free hormone concentration. A correction for changes 
in this free concentration can be made according to Oppenheimer et al (1970): 
fr~e MCR= total MCR (1/FF-1) (FF: free fraction). With this correction, it 
appeared that free T 4 MCR was normal or slightly increased during normal 
or reduced free T4 levels in the low TT4 state of NTI and decreased in the 
presence of elevated free T4 levels in the high and normal TT4 states of NTI. 
It was therefore suggested that changes in the free hormone clearance rate 
were responsible for alterations in serum free T4 levels. The total and free 
T 4 MCR may be affected by the rate of hormone transport from plasma into 
the tissues. The latter is determined by the quantity of T 4 in the vascular 
compartment and the fractional rate of hormone exit from plasma. It appeared 
that the fractional rate of T 4 exit from plasma was decreased to approximately 
50% in the high, normal and low TT 4 states of NTI, so serum levels of total 
or free T 4 or the free fraction of this hormone did not determine its fractional 
rate of transport from plasma into the tissues. This is in contrast to the increased 
and reduced fractional transport rates from plasma to the tissues in the low 
TBG state and high TBG state, respectively, in otherwise normal subjects. 
These observations point to an impaired transport mechanism in the above 
cited situations of NTI. For more details, the reader is referred to Kaptein 
(Thyroid hormone metabolism, ed. G. Hennemann, 1986). 
An universally decreased cellular uptake of T 4 or decreased exit of T 4 from 
plasma, however, cannot explain why rT3 production remains normal. A 
decreased T4 cellular availability would, in addition to a lowered T3 production, 
also result in a decreased rT 3 generation. Therefore, other or additional 
mechanisms must be operative. Considering the model as proposed by Krenning 
et al (1983) in which T4 and rT3 enter the cell by a common pathway that 
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is much more sensitive to a decreased cellular ATP content than the pathway 
for T3, a few assumptions have to be made in order to explain all changes 
in iodothyronines as seen during starvation. Firstly, it must be assumed that 
hormonal transport into different tissues is not inhibited to the same extent, 
but is most pronounced in the liver. Secondly, rT 3 production takes place mainly 
outside the liver in tissues not or to ,a lesser extent subjected to inhibition 
of transmembraneous transport of thyroid hormone and, thirdly, the liver is 
quantitatively important in the production of T3 and the degradation of rT3. 
As yet, no data are available to substantiate the first postulate. With regard 
to the production ofT 3, rT 3 and degradation of rT 3, evidence can be presented 
in favour of the above cited hypothesis. This will be discussed in the next 
section. 
Thyroid hormone deiodination is tissue-specific 
Because the T3 PR is impaired during starvation and NTI, in contrast to the 
unaltered rT 3 generation, it was suggested that the 5'- deiodination and 5-
deiodination were accomplished by separate enzymes. The 5'-deiodination is 
also termed: outer ring deiodination (ORO) and 5-deiodination is referred to 
as inner ring deiodination (IRO). It has become increasingly evident that in 
rat liver IRO and ORO are mediated by the same enzyme (Fekkes et al, 1982). 
This conclusion can be extrapolated to the human situation. That the enzyme 
kinetics of rat liver deiodinase are indeed applicable to human liver, is supported 
by recent findings in human liver homogenates (Visser et al, 1983). Because 
of a low Km and high Vmax for IRO of rT3, it is unlikely that the liver, although 
actively producing rT3, contributes significantly to the plasma rT3 pool (Visser 
et al, 1979). Reverse T3 could not be detected in the perfusate of T4 perfused 
rat livers (Kohrle et al, 1982) or incubation media of rat liver slices (Balsam 
and Ingbar, 1978) and cultured rat hepatocytes (Sato and Robbins, 1981) 
incubated with T 4. Furthermore, the net removal of rT 3 by the human liver 
equals about the total bodyremoval (Bauer et al, 1987). From these observations, 
it is now held that the liver is a major site in degradation of rT3, and that 
plasma rT 3 is not derived from hepatic T 4 to rT 3 conversion. The latter is 
further supported by the finding that plasma production rates of rT3 are similar 
in PTU and methimazole treated hyperthyroid patients (Laurberg and Weeke, 
1980). Propylthiouracil (PTU) inhibits 5'-deiodination in the liver, while 
methimazole does not. Thus, different organs may be involved in the production 
and clearance of a single hormone, and these organs do not necessarily react 
in the same way to situations as starvation, non- thyroidal illness or changes 
in thyroidal hormone secretion. The 5'- deiodinating enzyme in the kidney, 
for instance, which is quite similar to liver 5'0 (vide infra), is not reduced 
in activity during fasting (Kaplan et al, 1979). Moreover, it appeared that IRO 
and ORO activity is qualitatively and quantitatively not equally present in 
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Table 3. Characteristics of the pathways of iodothyronine deiodination 
in the rat 
Type I Type II Type Ill 
Deiodination site inner and outer ring outer ring only inner ring only 
Substrate preference rT3 >> T4 > T3 T4 > rT3 T3 > T4 
Kinetic pattern ping-pong sequential sequential 
Km forT 4 in microsomal ~ 1 ,u.M (1-5 mM OTT) ~ 1 nM (20 mM OTT) ~ 40 nM (50 mM OTT) 
preparations 
Tissue localization highest in liver, kidney and anterior pituitary; CNS; CNS; eye; placenta 
thyroid. Present in many brown adipose tissue; (human, rat) 
other tissues (low activity) placenta (human, rat) 
Thiol reductants Stimulatory Stimulatory Stimulatory 
lopanoic acid inhibitory inhibitory inhibitory 
PTU inhibitory no effect no effect 
Hypothyroidism liver, kidney: reduced activity increased activity in brain decreased 
thyroid: increased activity activity 
OTT dithiotreitol 
CNS : central nervous system 
PTU : propylthiouracil 
Data from Kaplan 1984 
different tissues (table 3). The type of monodeiodination in the liver and kidney, 
has been designated as type I. This type of enzymic activity is most abundant 
in liver and kidneys. The idea that these organs play a dominant role in the 
production ofT 3, originates from the observation that PTU, a specific inhibitor 
of type I activity, induces a 50-75% decrease in serum T3 concentration in 
thyroidectomized L-thyroxine substituted rats (Bernal and Escobar del Rey, 
1974; Silva et al, 1982). It has, however, been shown that in rat pituitary and 
brain, besides low levels of type I enzyme, two other types of deiodinase activity 
exist, referred to as type II and III (pituitary excluded, does not contain type 
III activity). Type II activity concerns ORD and type III IRD. All three types 
are thiol- dependent, but only type I is inhibited by PTU and has a different 
reaction mechanism compared to type II and III. Liver and kidney do not 
contain type II and III activity. Very interestingly, these enzymes differ essentially 
in their reaction to hypothyroidism. In the rat cerebral cortex, hypothyroidism 
induces an increase in type II activity with a concomitant decrease in activity 
in type III enzyme. These changes result in an increased T 3 production and 
diminished T3 degradation, thus preventing cerebral T3 depletion. In contrast, 
type I activity diminishes, resulting in a lowered T3 generation by type I 
containing tissues, which are believed to contribute mostly to the plasma T3 
pool. As yet, in humans no data are available with regard to changes in activity 
of these types of deiodinase during starvation and non-thyroidal illness. 
Sulfoconjugation of iodothyronines 
Regulatory mechanisms in thyroid hormone metabolism in various conditions 
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became even more complex when studies with cultured rat hepatocytes showed 
that sulfoconjugation and deiodination of T3 and 3,3'-T2 are strongly related 
processes (Otten et al, 1983, 1984; Visser et al, 1983a). Inhibition of sulfa-
transferase activity of cultured rat hepatocytes results in a decreased deiodination 
of these compounds. Sulfation of T 3 increases the V max of T 3 5-deiodination 
by approximately 30 times, without altering the Km (Visser et al, 1983). 
Subsequently, the effects of sulfation ofT4 and rT3 were evaluated. These studies 
(Mol and Visser, 1985) revealed that sulfation of T4 inhibits 5'-deiodination 
but 5-deiodination is greatly enchanced due to an increase in v max with a 
concomitant decrease in Km resulting in a 200-fold increase in the V maxiKm 
ratio. Sulfation of rT 3 does not appreciably influence its outer ring deiodination. 
It remains to be established to what extent sulfation of iodothyronines could 
act as a possible factor in regulating thyroid hormone metabolism. 
Summary 
Caloric deprivation and non-thyroidal illness induce the so called low T3 
syndrome, in which reduced serum T3 1levels are found in concomitance with 
elevated serum rT3 concentrations. In addition to the amount of caloric intake, 
manipulations in dietary composition have also been shown to influence these 
changes in rather specific, as yet not completely understood, ways. In caloric 
deprivation total serum T 4 levels are mostly unaltered, while in non-thyroidal 
illness total serum T4 levels are increased, normal or decreased, roughly in 
parallel with the degree of illness. Kinetic analysis revealed that reduced serum 
T3 levels in these situations result from a diminished production rate, while 
its MCR is unchanged. This is in contrast to the normal PR of rT3 and the 
increase in serum levels of this iodothyronine is explained by its reduced MCR. 
This led to the idea that a selective decrease in ORD in the liver, as had 
been shown in liver homogenates from fasted rats, was responsible for the 
alterations in iodothyronines as cited above. However, ORD and IRD activity 
in rat liver could not be separated and it became evident that deiodinase activity 
was quantitatively and qualitatively not equally distributed over different tissues. 
Deiodinase activity could be attributed to three different enzymes of which 
some features are summarized in table 3. It also appeared that the liver must 
be regarded as a major site in T3PR and degradation of rT3. This had already 
been postulated by Krenning et al (1983) in order to explain the changes in 
serum thyroid hormones during the low T3 syndrome alternatively i.e. by 
inhibition of transmembraneous transport of iodothyronines. According to this 
model, T4 and rT3 enter the hepatocyte by a common pathway that is much 
more sensitive to inhibitory factors than the pathway for T3. A decreased T4 
entrance in the liver with type I enzyme activity results in a diminished T3 
production. As has been outlined above, rT3 production in the liver does not 
contribute significantly to the plasma rTrconcentration, thus no influence on 
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the rT 3 plasma production rate is to be expected from a decreased T 4 entrance 
in the liver. In contrast, a decreased entrance in the liver of plasma rT3, which 
is thought to be produced by extrahepatic type III enzymic activity containing 
tissues, would result in an increased plasma rT3 concentration, since the liver 
is considered as the major rT3 degrading organ. In order to explain the unaltered 
rT 3 production rate, it must be assumed that rT 3 producing tissues are not 
or to a lesser extent subjected to this inhibition of transmembraneous transport 
of iodothyronines. Degradation of T 3 is mediated by type I and III enzymic 
activity. Because T 3 entrance is much less sensitive to this transport inhibition, 
its unaltered MCR can thus be explained. The idea that changes in transport 
of iodothyronines into the tissues may indeed appear to be an important factor 
in explaining the above mentioned alterations in serum iodothyronines, is further 
supported by the in vivo observations in patients with non-thyroidal illness. 
Taken together, the conclusion can be reached, that in explaining changes in 
iodothyronines during the low T 3 syndrome, several mechanisms must be taken 
into account, i.e. the qualitative and quantitative contribution of changes in 
enzymic deiodination activity, changes in cofactors and possibly sulfation of 
substrates for these reactions and alterations in transport of iodothyronines 
into the tissues. These considerations probably also apply for other conditions 
in which serum iodothyronines change in a predictable, reversible and repro-
ducible way, such as during administration of propranolol, dexamethasone, 
amiodarone and cholecystographic agents. It is feasible that different mecha-
nisms are operative in the diversity of conditions in which a low T3 syndrome 
originates. 
Scope of the thesis 
The results from the work of Krenning and Docter in our laboratory, as discussed 
in previous sections, led to the hypothesis that inhibition of transmembraneous 
transport of iodothyronines, could be a major factor in inducing the hormonal 
changes in the low T 3 syndrome. A three-pool model of distribution and 
metabolism ofT 4, T 3 and rT 3 was used for kinetic analysis. 
Two conditions in which a low T 3 syndrome is known to originate, were 
studied: caloric deprivation and oral administration of propranolol. 
Chapter 2 deals with alterations in kinetic parameters during caloric 
deprivation in 10 obese subjects. The same parameters were assessed in six 
normal non-obese L-T4 replaced male students before and during D- propranolol 
treatment. The results obtained in this latter group are presented in chapter 
3. In chapter 4 early serum disappearance and computed liver uptake of thyroxine 
in humans during caloric deprivation and D-propranolol administration are 
discussed. In addition, both parameters were assessed immediately after in-
travenous administration of fructose, a manoeuvre by which a prompt and 
significant fall in liver A TP is induced. In chapter 5 the results from the above 
mentioned sections are summarized. 
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CHAPTER2 
EFFECTS OF CALORIC DEPRIVATION ON THYROID 
HORMONE TISSUE UPTAKE AND GENERATION OF LOW. 
T3 SYNDROME 
J.T.M. van der Heyden, R. Docter, H. van Toor, J.H.P. Wilson, 
G. Hennemann, E.P. Krenning 
Abstract 
Changes in thyroid hormone. metabolism in the low T3 syndrome .cannot be 
fully explained in all conditions by a decrease in 5'-deiodinase activity. Recent 
observations showed that in rat hepatocytes iodothyronines are taken up by 
an active transport mechanism. In order to investigate if regulation i.e. inhibition 
of active transmembraneous transport for iodothyronines in humans may 
contribute to the generation of the low T3 syndrome, tracer thyroxine (T4) 
and 3,5,3'-triiodothyronine (T3) kinetic studies were performed in ten obese 
subjects before and after seven days on a 240 kcal diet. Kinetic analyses were 
performed according to a 3-pool model of distribution and metabolism for 
both T4 and T3. 
T4 kinetics: during caloric deprivation serum total T4 (93 ± 2.8 vs 91 ± 
3.3 nmol/1) (control versus 240 kcal diet, mean ± SEM) and plasma pool 
(388 ± 33 vs 355 ± 19 nmol) did not change, and production rate (124 ± 
11.1 vs 97 ± 6.7 nmolld) and metabolic clearance rate (MCR) (1.32 ± 0.09 
vs 1.07 ± 0.071/d) were significantly lower (p <0.005). · 
Despite a significantly higher serum free T4 (20 ± 1.2 vs 25 ± 1.9 pmol/ 
1) (p <0.001), the mass transfer rate to the rapidly equilibrating pool (REP) 
(195 ± 13 vs 137 ± 10.9 nmol/h) (p <0.005) and the slowly equilibrating 
pool (SEP) (16.9 ± 3.0 vs 9.2 ± 2.3 nmol/h) (p <0.005) diminished significantly, 
leading to smaller tissue pools (REP: 539 ± 42 vs 434 ± 36 nmol and SEP: 
423 ±52 vs 262 ± 43 nmol) (p<0.025; p <0.005 resp.). 
T3 kinetics: both serum total T3 (1.7 ± 0.1 vs 0.9 ± 0.04 nmol/1) (p <0.001), 
free T3 (3.5 ± 0.3 vs 2.6 ± 0.2 pmol/1 (p <0.001), plasma pool (9.8 ± 1.0 
vs 5.5 ± 0.6 nmol) (p <0.001) and production rate (49 ± 4.9 vs 28 ± 2.6 
nmol/d) (p <0.001) diminished significantly, while MCR (27.9 ± 2.0 vs 30.5 
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± 2.2 1/d) remained unchanged. Mass transfer rates to the REP (19.3 ± 1.8 
vs 10.1 ± 1.1 nmol/h) (p <0.005) and the SEP (6.1 ± 0.5 vs 3.5 ± 0.4 nmol/ 
h) (p <0.001) were lowered by about 50%, leading to smaller tissue pools 
(REP: 6.8 ± 0.8 vs 4.1 ± 0.3) (p <0.025) (SEP: 44.4 ± 4.5 vs 27.1 ± 2.3 
nmol) (p=O.Ol). These changes cannot be fully explained by a similar decrease 
of serum free T3 (only 25%), indicating a diminished transport efficiency for 
T3. 
It is concluded that during caloric restriction transport of T 4 and T 3 into 
tissues is diminished and that this phenomenon is much more pronounced 
for T 4 than for T 3· It is postulated that, irrespective of any possible change 
in 5'-deiodinase activity, inhibition of T4 transport per se may contribute to 
low T3 production and low T3 serum levels due to less substrate (i.e. T4) 
availability in tissues. 
Introduction 
It was originally envisaged that iodothyronines enter the cell by simple diffusion 
(27). This notion was based on the lipophilicity of iodothyronines which favours 
the passage through the lipid bilayer of the cell membrane. In this view the 
translocation of iodothyronines over the cell membrane is governed by the 
difference in intra- and extracellular free concentration, i.e. the concentration 
of the non protein-bound iodothyronine. It is then to be expected that turnover 
of iodothyronines is more closely related to the free extracellular concentration 
than to the total concentration. However, normal or even decreased thyroxine 
(T 4) turnover has been found in several conditions for example non-thyroidal 
illness and the post-operative state despite the presence of increased free hormone 
serum levels (10). Even in euthyroid normals free T4 concentration did not 
correlate with T4 turnover (10). Moreover, in thyroxine binding globulin (TBG) 
deficiency with lowered serum free T4 concentrations a normal T4 turnover 
has been found. It was postulated that other factors, possibly directly related 
to cellular handling ofT 4, may be operative (10). 
Caloric deprivation in humans induces the so called low T 3 syndrome in 
which the total (and free) serum levels of 3,5,3'-triiodothyronine (T3) are 
decreased and those of 3,3',5'-triiodothyronine (reverse T3, rT3) increased (3,4). 
Tracer kinetic studies revealed a diminution of T3 production while rT3 
generation was unchanged (35,36). The metabolic clearance rate of rT3 was 
decreased and that of T3 unchanged (35,36). These phenomena have been 
explained by a decreased 5'- deiodinase enzyme activity in the liver leading 
to a diminished rT 3 breakdown and T 3 production. In liver homogenates of 
fasted rats a reduced 5' -deiodinase activity could indeed be demonstrated (9). 
However, a reduced 5'-deiodinase activity cannot fully explain the alterations 
in this syndrome since serum T3 and rT3 do not always change reciprocally. 
In contrast to a sustained reduction of serum T 3 in humans during starvation, 
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only a transient rise in rT3 was observed in some studies (4). After two to 
three weeks rT 3 levels start to decline. Because of this and other (see discussion) 
considerations one should look for other factors which could participate in 
the induction of the low T3 syndrome as well. Recently, we have demonstrated 
the presence of a specific high affinity low capacity energy dependent cellular 
uptake mechanism for T4, T3 and rT3 in rat hepatocytes in primary culture 
(21-24). According to kinetic experiments, T4 and rT3 seem to enter the cell 
by a common pathway that is different from that for T3. Both pathways have 
been shown to be A TP dependent (22,23). These observations led us to consider 
the possibility that inhibition of transmembraneous transport of iodothyronines 
could be a factor in the generation of the low T 3 syndrome. 
To investigate this aspect we have performed tracer kinetic studies with T4 
and T 3 in obese subjects before and during a low caloric intake leading to 
a low T 3 syndrome. Data were analyzed according to a three compartmental 
model of distribution and metabolism, as developed by DiStefano et al (5, 
6). 
Glossary 
Nomenclature used 
(i = 1, 2, 3;j = 1, 2, 3;i#j) 
t = time (h) 
Yt = plasma activity at time t (% dose/1) 
A; coefficient of the i1h exponential component(% dose) 
= exponent of the i1h exponential component (h-1) 
Q1 = size of pool1 (plasma pool) (nmol) 
Q2 = size of pool 2 (fast or rapidly equilibrating pool (REP)) (nmol) 
Q3 = size of pool 3 (slow or slowly equilibrating pool (SEP)) (nmol) 
K;; = fractional turnover rate of pool i (h-1) 
K;i = fractional transport rate from pool j to pool i (h -J) 
Ko; = fractional disposal rate in pool i (h-1) 
MCR = metabolic clearance rate (1/h) 
V; = plasma equivalent distribution volume in pool i (I) 
Ds = disposal rate in the slow pool 
DF = disposal rate in the fast pool 
CRs = T 4 --> T 3 conversion rate in the slow pool 
CRF = T 4 --> T 3 conversion rate in the fast pool 
SR secretion rate from the thyroid 
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Methods 
Subjects 
Ten otherwise healthy obese subjects (nine females), age 21-36 years (mean 
31 years), participated in this study. All had normal thyroid function as measured 
by total serum T4, T3-resin uptake and thyrotropin response to an intravenous 
bolus of thyrotropin releasing hormone. The study and the protocols were 
approved by the Ethical Committee of the medical centre and informed consent 
was obtained from all participants. Medications if used were omitted for at 
least 1 month before the study. Body weights ranged from 75 --155 kg (mean 
113.5 kg) at the start. All subjects were at least 25% overweight, range 26 
- 198 percent (mean 97%). -, 
During the control study period patients were kept on a normal weight-
maintaining diet. The study was repeated after six weeks, when the subjects 
were on a 240 kcal ModifastR diet for seven days. This diet contained 33 g 
protein, 25.5 g carbohydrate and 0. 7 g fat and adequate supplies of minerals 
and vitamins. 
Materials and Preparations 
125l-T4 (specific activity >1200 uCi/ug) and Na131l for labeling were purchased 
from The Radiochemical Centre, Amersham, U.K. 131I-T3 was prepared by 
iodination of 3,5-T2 with 1311= by the chloramine-T method (8). Iodination 
was performed by mixing 10 ul volumes of Na131I, 0.5 M sodium phosphate 
buffer pH 7.5, 3,5-Tz (1 ug/ul in 0.05 M sodium phosphate buffer pH 7.5) 
and chloramine-T (1 ug/ul in 0.05 M sodium phosphate buffer pH 7.5), in 
that order. After one minute the reaction was terminated by adding 100 ul 
sodium bisulfite (1 ug/ul in sodium phosphate buffer pH 7.5). The reaction 
mixture was applied on a small (10x0.5 em) Sephadex LH-20 column and eluted 
with 30% ethanol in 0.05 M sodium carbonate pH 11.5 (v/v). T3-fractions 
were pooled and evaporated to dryness under a stream of nitrogen. 
T3-antiserum was obtained by injecting rabbits with a T3-bovine serum 
albumin conjugate in complete Freund's adjuvant. Antiserum against T4 was 
purchased from Henning GmbH, Berlin. All other reagents used were of the 
highest purity available. 
Procedures 
25 uCi 125l-T4 and 30 uCi 131l-T3 in 1.5 ml of 2% human albumin in phosphate 
buffered saline, were administered via an intravenously inserted cannula in 
the arm and blood samples were drawn at regular intervals through a cannula 
in the contralateral arm to obtain at least six points on each of the three 
sections into which the plasma disappearance curve could be resolved. Patients 
were in supine position from one hour before and during the first four hours 
of the study. Later on blood samples were collected after the patients had 
been in supine position for at least half an hour. Samples were collected during 
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ten days. During the study ten drops of Lugol's solution were administered 
three times a day in order to prevent thyroid uptake of radioactive iodide 
liberated during the study. For counting 125I-T4 activity, 1 ml serum samples 
were precipitated with 4 volumes 10% trichloroacetic acid (TCA) and washed 
twice with 10% TCA. 131I-T3 was separated from serum by the method of 
Bianchi et al (2) with modifications. Serum samples (0.5 ml) were mixed with 
0.5 ml buffer (0.08 M barbital pH 8.6, 9 mg/ml 8-anilino-naphtalene sulfonic 
acid (ANS)) and applied to a small (10x0.5 em) Sephadex G-25 column 
equilibrated with 0.1N NaOH. Proteins, including iodoproteins and iodide were 
eluted with 5x0.5 ml barbital buffer (0.08 MpH 8.6, 0.6 mg/ml ANS). Thereafter 
131I-T3 was eluted with 5x0.5 ml barbital buffer containing specific T3-antibody, 
and fractions were pooled before counting. Rabbit T3-antiserum (1 ml, binding 
capacity 2.5 nmol T3/ml) was precipitated with 1.8 M (NH4)2S04 final 
concentration. The precipitated anti-T 3-antibody was dissolved in barbital buffer 
and diluted to 100 ml before use. Recovery of added labeled T3 from serum 
samples was 99.0 ± 0.15% (mean ±SD, n=10). The injected dose was diluted 
100 fold in the subjects' serum and processed as outlined for the serum samples, 
for use as standard. 
Free T4 and T3 concentrations were determined by equilibrium dialysis 
according to the method of Sterling and Brenner (33). 
Serum rT 3 was estimated by radioimmunoassay (38). T 4 and T 3 were measured 
by established radioimmunoassay procedures, using ANS to inhibit binding 
of the hormones to serum proteins. 
Calculations 
All tracer concentrations y(t), expressed as the percent injected dose per liter, 
were fitted to the sum of 3 exponentials as · 
where t is time, Ai is the coefficient and Ai is the constant of the exponent 
of the i-th exponential. Estimation of the goodness of fit was performed by 
comparing the residual sum of squares with the total sum of squares of all 
data points. From the exponents and coefficients obtained the plasma dis-
tribution volume Vp can be calculated. 
and the metabolic clearance rate MCR as 
Furthermore the exponents (Ai) and coefficients (Ai) were used to calculate 
the turnover rates of the plasma pool (KII), the rapidly equilibrating pool 
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~ CR 5 ~ SR ~ CRf 
"slow"pool ~ plasmapool kij. "fast"pool 
03 .. 01 • 
Q2 
SEP k13 k12 REP 
~ k03 'k02 
D5 = 03 x k03 Df= 02 X k02 
Computable from blood-borne data 
-ku k21 + k31 > 0 cl = k12 X k21 > 0 
-k22 k12 + ko2 > 0 c2 = kl3 X k31 > 0 
-k33 = k13 + ko3 > 0 
Fig. 1. Three pool model of iodothyronine distribution and metabolism. The K;i values (i#j. 
i, j=1, 2, 3, all Ku >O) are fractional transport rates (hours-1) from pool j to pool i.,KJ,, 
K22 and K33 are fractional turnover rates (hours-1 of pool 01, pool 02 and pool Q3, respectively. 
The relations at the bottom are the combinations of these parameters computable from 
data obtained by blood sampling only. For a complete list of nomenclature see Glossary. 
For evaluation of the T4-model only secretion (SR) of T4 into the plasma pool should be 
considered, while for evaluation of the T3-model also T3-production by conversion both in 
the slowly equilibrating pool (CRs) and in the rapidly equilibrating pool (CRF) should be taken 
into account. 
(K22) and the slowly equilibrating pool (K33) respectively, and the constants 
C1 and C2 of the three pool model ofiodothyronine distribution and metabolism 
depicted in fig. 1. This model and the mathematical solution was recently 
described by DiStefano et al. both for T3 (5) and for T4 (6). 
Rearrangment of the terms depicted in fig. 1 gives 
which equality describes the value of Kz~, the fractional transfer rate constant 
from plasma to the rapidly equilibrating pool. A minimal value for Kz1 can 
be found if Koz (the fractional disposal rate constant from REP) is arbitrarily 
set at zero, which means absence of disposal in this fast pool. A maximal 
value for Kz1 can be found if Ko3, the fractional disposal rate constant from 
the SEP is put at zero, which means absence of disposal in the slow pool. 
It appeared that the difference between the maximal and minimal value is 
only small both for the T4 and for the T3 model (Table 1). Therefore the 
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Table 1. 3 pool model for T4- and T3-kinetics 
lower bound 
upper bound 
difference 
Upper and lower boundaries for K21 
(fractional tran1sfer rate from plasma to the 
REP). h-1 
0.51 0 ± 0.037 
0.523 ± 0.037 
2.12% ± 0.20 
1.929 ± 0.172 
2.137 ± 0. 1 76 
10.6% ± 0.8 
Values are means± SE (n = 1 0). 
mean of these two values was used in the further calculations. Use of this 
mean value inevitably divides the disposal equally between the slow and the 
fast pool. When K21 can be approximated in this way, all other parameters 
of the model depicted in fig. 1 can be calculated. 
Further parameters used in this paper were calculated essentially as described 
by DiStefano et al. (5,6). 
Results 
In all 10 subjects a low T3 syndrome was induced. Serum T3 levels decreased 
by 46% i.e. from 1.71 ± 0.07 nmol/1 (mean ± SEM) in the control period 
to 0.93 ± 0.04 nmol/1 after 7 days of caloqc deprivation. Serum rT3 levels 
increased by 53% from 0.28 ± 0.04 to 0.43 ±' 0.07 nmol/1 respectively. Serum 
T4 concentrations did not change (93 ± 2.8 versus 91 ± 3.3 nmol/1). During 
the first two weeks of caloric restriction a considerable body weight reduction 
was seen in all persons (6.4% ± 0.1). 
All plasma radioactivity disappearance curves of T4 and T3 could be fitted 
to a t4ree exponential model. A typical example for T3 is shown in fig. 2. 
Residual mean square for all disappearance curves was about 0.1% of total 
mean squares indicating excellent fit of the data points to this model (32). 
The values of K21 and K31 for T4 and T3 may depend on the location where 
these iodothyronines are metabolized, i.e. the slowly and/or the rapidly 
equilibrating pool. Since no precise information is present in this respect it 
was calculated to what extent the location of the disposal of T 4 and T 3 would 
actually affect the K21 and K31 for these hormones. To reveal the relationship 
between the transfer rate constants K21 and K31 and the disposal of T3 and 
T4 in the slowly and the rapidly equilibrating pooi, ·we have calculated all 
parameters of the model with values of K21 ranging from the minimal to the 
maximal value and plotted the K21 and K31 as a function of the disposal in 
the rapidly equilibrating pool, both for the T4 model (fig. 3) and the T3 model 
(fig. 4). A virtually absent (maximal 2.5%) change for T4 and small change 
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Fig. 2. Typical example of the description of a T3·disappearance curve by a three exponent 
model. Panel A: plot of log y, (in % Dose/1) against time, with the least squares regression 
line on the final straight part of the curve, giving estimates of coefficient A3 and exponent 
A.3. Panel B: plot of log [y(t) - A3e-"'1] against time, with the least squares regression line 
on the straight part of the curve, giving estimates of coefficient A2 and exponent A.2. Panel 
C: plot of log [y(t)- A2e-M-A3e-MJ against :time, giving estimates of coefficients Ai and 
exponent At. MCR=25.0 1/day; Vplasma=5.0 I; residual sum of squares=0.098, total sum 
of squares=64.15. 
• E kzl 
.6 •• kJl 
h-1 
• • • • • 
• 4 
fractional 
transfer .z 
r-ate 
• • • • 0 • 
0 2 3 4 5 
111101/h 
Disposal r-ate from the REP 
Fig. 3. 3 pool model for T4-kinetics. Relation of the transfer rate constants to the fast pool 
(K21) and the slow pool (K3t) on the disposal rate from the fast pool. Because the total disposal 
of T4 (the sum of the disposals in the slow and the fast pools) is constant and can be 
calculated from the plasma T4 concentration and the MCR, a similar (but inverse) relationship 
can be found between K21, K3t and the disposal rate from the slow pool. 
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h-1 
fractional • " kzl 
transfer 1. • " kJl 
rate 
• • • • • 0 
0 nmol/h 2 
Disposal rate from the REP 
Fig. 4. 3 pool model for T3-kinetics. 
Relationship of the transfer rate constants to the fast pool (K21l and the slow pool (K3t) 
on the disposal rate from the fast pool. For further details see the legend of fig. 3. 
(max. 10%) for T3 i~ s.een for K21 and K31, indicating that the choice of the 
pool in which the disposal actually takes place is not relevant for the calculations 
of K21 and K31· Taking the mean of the minimal and maximal value of K21 
will therefore give mel:mingfull information about the fractional transfer rates 
and mass transfer rates'to the slow and the fast pool. Taking these considerations 
into account, the turnover data of T4 and T3 ir;t 10 obese subjects before and 
during caloric deprivation can be analysed. 
Thyroxine (see Table 2). 
Caloric deprivation did not alter significantly plasma total T4 levels, plasma 
T 4 pool and the size of the T 4 plasma compartment. Both the slowly equilibrating 
pool (SEP) and the total tissue pool diminished as did the mass transfer rates 
and fractional transfer rates to the rapidly equilibrating pool (REP) and SEP. 
These data indicate that transport of T4 into the tissues is diminished during 
caloric deprivation, resulting in smaller tissue pools of thyroxine. Furthermore, 
as is illustrated in Table 2, significant increases were observed in serum levels 
of free T4. It should be noted that a diminution of mass transport of thyroxine 
into tissues is present while free hormone levels are increased. If the mass 
transfer rate is divided by the free hormone concentration, a "transport efficiency 
ratio" is obtained, which corrects for changes in free hormone concentration. 
In this way a 44% and 56% transport inhibition can be calculated for REP 
and SEP, respectively. Without correction these values are 30% and 46% 
respectively. The MCR and the production rate of T4 decreased significantly 
during fasting. 
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Table 2. T3 and T4 kinetics in 10 obese subjects before and during caloric deprivation 
control caloric deprivation 
T4 T3 T4 T3 
Production rate nmol/d 124 ( 11 .1) 48.6 (4.90) 97 (6. 7)" 28.4 (2.60)b 
MCR 1/d 1.32 (0.09) 27.9 (2.0) 1.07 (0.07)" 30.5 (2.2) 
Plasma compartment 
free hormone concentration pmol/1 20 (1.2) 3.5 (0.3) 25 ( 1.9)b 2.6 (0.2)b 
hormone concentration nmol/1 93 (2.8) 1.71 (0.07) 91 ( 3.3) 0.93 (0.04)b 
size I 4.1 (0.29) 5.6 (0.36) 3.9 (0.16) 5.9 (0.48) 
pool nmol 388. (33) 9.8 (1.0) 355 (19 ) 5.5 (0.57)b 
Rapidly equilibrating compartment 
w size I 5.8 (0.45) 3.9 (0.39) 4.8 (0.42)' 4.5 (0.32) 
00 pool nmol 539 (42) 6.8 (0.82) 434 (36 )d 4.1 (0.30)d 
mass transfer rate from plasma nmol/h 195 (13) 19.3 (1.75) 137 (10.9)" 10.1 (1.06)" 
fractional transfer rate from plasma h-1 0.55 (0.08) 2.03 (0.17) 0.39 (0.03)' 1.9 (0.17) 
Slowly equilibrating compartment 
size I 4.5 (0.43) 25.8 (2.53) 2.8 (0.43)b 29.4 (2.24) 
pool nmol 423 (52) 44.4 (4.47) 262 (43 )" 27.1 (2.27)[ 
mass transfer rate from plasma nmol/h 16.9 (3.0) 6.13 (0.48) 9.2 (2.3)" 3.48 (0.35 )b 
fractional transfer rate from plasma h-1 0.045(0.009) 0.64 (0.024) 0.025(0.006)" 0.63 (0.022) 
Values are means± SE.MCR, metabolic clearance rate. T4 1 nmol/1=0.077 J.Lg/dl; T3 1 nmol/1=0.065 J.Lg/dl. 
"P <0.005; b P<0.001; c P<0.01; d P<0.025; 'P=0.05 (paired t-test); r P=0.01. 
Triiodothyronine (3,5,3'-T3) (Table 2). 
All T3 pools decreased by approximately 40% (plasma pool 44%; REP 40%; 
SEP 43% ). Also inward mass transfer rates of the REP and the SEP decreased 
by a similar value (REP 48%; SEP 43%), while free T3 decreased by appro-
ximately 25%. If a transport efficiency ratio for T3 is calculated in the same 
way as outlined for T4, a transport inhibition during caloric restriction of 30% 
and 23% is found for REP and SEP respectively.The fractional transfer rates 
did not alter. 
Discussion 
In general, the low T 3 syndrome is explained by diminution of 5'- deiodinase 
enzyme activity causing reciprocal changes in serum T3 and rT3. The low T3 
syndrome due to caloric deprivation or fasting in man is caused by a decrease 
in T3 production and in plasma rT3 removal (35,36). Although, until the present 
study, no information was present about the mechanism of these changes in 
man, it was hypothesized that the underlying cause is a reduced 5'-deiodinase 
activity in the liver. This notion was derived from studies in fasted rats where 
indeed a reduced liver 5'-deiodinase activity has been found (9). This decreased 
activity, which is caused by a decrease in enzyme protein (1,17) has been 
attributed to tissue hypothyroidism induced by decreased T 4 production, because 
enzyme activity was restored in microsomal fractions upon T 4 replacement 
(1,7). It was suggested, however, that 5'-deiodinase activity is only rate limiting 
in fasting rats, when supraphysiological concentrations of T4 are used (15). 
In addition, it is not excluded, that changes in thiol availability also play a 
role in decreased 5'-deiodinase activity in fasted rats (37). Studies from others 
(15) using perfused livers of 3 days fasted rats showed a decrease in uptake 
ofT 4, while the efficiency ofT 3 production from the T 4 taken up was unimpaired. 
It seems, therefore, questionable to explain the low T3 syndrome solely by 
diminution of 5'-deiodinase activity. 
An alternative explanation for the genesis of the low T3 syndrome may be 
inhibition of transport of iodothyronines across the cell membrane. From data 
in ourlaboratory (21-24) it became apparent that two different transport systems 
for iodothyronines can be discerned in rat hepatocytes in primary culture: one 
pathway shared by T4 and rT3 and a different one for T3. Inhibition of these 
active transport systems could be achieved by a fasting-like state, i.e. incubation 
of hepatocytes with decreasing amounts of glucose. Based on these conside-
rations it is attractive to speculate that transmembraneous transport of T4 may 
be of rate limiting significance in peripheral T 3 production during fasting .. Thus, 
if similar transport mechanisms for iodothyronines, as shown in rat hepatocytes, 
exist in man, an alternative or additional explanation for induction of the 
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low T3 syndrome in these conditions can be given. Available literature (12) 
points to an energy dependent T3 uptake in cultured IM-9 human lymphocytes 
and recently we were able to find specific energy dependent T3 and T4 uptake 
in cultured human fibroblasts (20). Therefore we have assessed the influence 
of a low caloric intake on mass transfer rates of T4 and T3 into tissue pools. 
Serum disappearance curves of T 4 and T 3 could be described by the sum 
of three exponentials in all subjects studied. This is in concert with the results 
described by others (19). A three compartmental analysis as outlined in the 
calculations could thus be applied. From fig. 3 and 4 and table 1 it can be ' 
concluded that the fractional transfer rate constant from plasma to REP (=K21) 
is not dependent on the site of the disposal. Differences between minimal and 
maximal values of K21 are virtually absent or small for T4 and T3 respectively. 
For all further calculations the mean of the maximal and minimal valuee 0f 
K21 was used, i.e. arbitrarily the disposal of both hormones was taken to occur 
for 50% in each pool. Because of the small differences in the transfer rate 
constants with respect to the assumed place of disposal, all results as shown 
in table 2 are valid without restrictions. 
DiStefano et al. has argued both for T3 (5), as for T4 (6), that the REP 
is mainly composed of liver and kidney, both on the basis of the rapid 
equilibration of these tissues with plasma T4 and T3, as on the size .of the 
hormone pools in these organs. 
Serum free T 4 levels increased during caloric deprivation by 25%, while total 
T4 levels remained unchanged.J'hese findings correspond with earlier reports 
(3,18), and indicate a decrease in plasma hormone binding capacity. Others 
(4) found a decrease in total T4 without a change in free T4. During fasting 
a blunted TSH response to TRH is observed (3,4), which can be explained 
by the increased free T4 levels, assuming that no, or less inhibition of trans-
membreanous transport of iodothyronines arises in the pituitary from caloric 
deprivation; This assumption is supported by the recent finding (34) that 
diminished TSH secretion in the starved rat is due to enhanced thyroid hormone 
activity at the pituitary level. An other possibility is that inhibition of TSH 
secretion in caloric restriction in men is caused by a similar central mechanism 
reported to occur in severe non- thyroidal illness (39). In the latter group of 
patients the drop in TSH secretion is seen as a primary event prior to a decrease 
in T 4 production. A diminution in TSH secretion will give rise to a decreased 
production rate of T4, as found in this study. The decrease in T4 MCR explains 
the unchanged serum ·total T4 level. In spite of an increased free T4 serum 
level · during caloric deprivation, hormone transport into REP and SEP is 
markedly decreased. This transport inhibition and decreased production rate 
can account for the observed decrease in tissue pools of T4. In this context 
it. is very interesting that in T 4 substituted fasting rats serum thyroxine 
concentration doubled within 48 hours of starvation (13). Decreased faecal 
excretion of T4 was only partially responsible for this increase. In addition 
a reduced clearance ofT 4 from plasma was found. 
40 
In this study both serum total T3, free T3, plasma pool and production rate 
(table 2) diminished significantly, while MCR remained unaltered. Mass transfer 
rates to SEP and REP were lowered by about 50%, leading to smaller pools 
(about 40%). A 50% decrease in serum total T3 with a concomitant decrease 
in serum free T3 of only 25% is likely due to a diminished plasma hormone 
binding capacity as seen with respect to T4. Although a 50% decrease in T3 
transport into the tissues can be partially explained by a similar decrease in 
T3 production rate, an additional factor in the decrease in inward mass transfer 
rates is an inhibition of transport into tissue cells because free T3 decreased 
only by 25% and the free hormone concentration in the interstitial fluid equals 
that in plasma (14). This transport inhibition ofT4 and T3 is particularly reflected 
by the decreased transport efficiency ratios, which corrects for changes in the 
free hormone concentration. 
The much more pronounced inhibition of T 4 transport into tissues as 
compared to that of T3 as found in this in vivo study, is in accordance with 
.similar findings with ATP depleted rat hepatocytes (22). Although T4 transfer 
rate into tissues, especially the REP, exceeds T4 disposal many times, there 
are arguments that a decrease in T 4 influx will lead to a decrease in T 4 metabolism 
and hence T 3 production. Thus, we have shown that efflux ofT 4 from hepatocytes 
is not dependent on energy and nonsaturable even far above the physiological 
range of free T4 (11). Because efflux of T4 seems to be a passive process, 
intracellular free T 4 is primarily dependent on the activity of the influx process. 
A decrease of this activity will lead to a lowering of intracellular free T 4 and 
thus to a diminished occupancy of enzymes involved in metabolism of T 4· 
This reasoning supposes the existence of a free hormone gradient over the 
plasma membrane. Recently the existence of such a gradient has been 
demonstrated. (29). In this way, an attenuation of T4 influx will result in 
diminished occupancy of 5'-deiodinase and consequently decreased T3 pro-
duction and also to a diminished occupancy of other binding proteins in the 
cell, explaining the smaller tissue pools observed. A similar mechanism was 
recently found in perfused rat liver (15). Diminished affinity or capacity of 
the intracellular binding proteins during fasting could however also (at least 
in part) be an explanation for these smaller pools. Unfortunately the model 
used in this study is not able to differentiate between these two options, and 
no data about changes in human tissue binding proteins during fasting are 
available. Taken together, it is clear from our study, that in addition to a 
possible inhibition of 5'-deiodinase enzyme activity, the low T3 syndrome during 
fasting should at least partly be explained by inhibition of transmembraneous 
transport of iodothyronines. 
With respect to the question if inhibition ofT 4 to T 3 conversion could explain 
the observed findings, we have attempted to estimate the conversion ratio before 
and during fasting. As it has been estimated that thyroid T3 secretion contributes 
about 20% to total T 3 production (26) after correction for this, a mean conversion 
ratio of 31% can be calculated in the control period. For calculation of the 
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conversion ratio during caloric deprivation the following reasoning has been 
pursued. As it is known that increased serum TSH predominantly stimulates 
thyroidal T3 secretion over T4 secretion it may be inferred that in the reversed 
situation i.e. decreased TSH activity T 3 secretion is at least as much depressed 
as T 4 secretion. As mean T 4 secretion in our subjects during caloric deprivation 
is depressed by 22%, let us assume that T3 secretion from the thyroid is as 
much depressed as thyroidal T4 secretion i.e. also by 22%. The thyroid then, 
will contribute with only 15% to total T3 production. Correcting for this, a 
conversion ratio during caloric deprivation is calculated of 25% as compared 
to 31% in the control period. Admittedly these values are approximations but 
it seems unlikely that these differences in T4--->T3 conversion ratio's can fully 
explain a mean decrease of T 3 production during caloric deprivation of 42%. 
It is however quite possible that decreased 5'-deiodinase activity plays an 
additional role in the induction of the low T 3 syndrome during caloric 
deprivation. 
Possibly a low T3 syndrome can be induced by several different mechanisms 
which may depend on the cause, i.e. type of disease, diet, drugs etc. As outlined 
above, the low T 3 syndrome during fasting can be explained at least in part 
by 5'-deiodinase inhibition in the rat. Without having studied 5'-deiodinase 
activity we ·find evidence that inhibition of thyroxine transport into tissues 
may contribute to the low T 3 syndrome in humans. As to the cause of this 
transport inhibition only speculation is possible at this stage. Although 
diminished intracellular ATP is seen in perfused livers from fasted rats (31) 
it is not. known whether caloric restriction in humans leads to a decrease of 
the intracellular energy charge which could result in decreased uptake of notably 
T4. Another possibility arises from the notion that dietary manipulation may 
lead to attenuation of membrane fluidity causing a decrease in Na-K-ATPase 
activity onhe hepatocyte (30). Since uptake of thyroid hormone is dependent 
on the sodium gradient over the plasma membrane (21), this mechanism may 
also be operative in our subjects. Finally the question is not solved to what 
extent the presence of a circulating inhibitor of hepatocyte iodothyronine uptake, 
which is found in severe non-thyroidal illness (28), plays a role in our findings. 
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CHAPTER3 
THREE COMPARTMENTAL ANALYSIS OF THE EFFECTS 
OF d-PROPRANOLOL ON THYROID HORMONE KINETICS 
J.T.M. van der Heyden, E.P. Krenning, H. van Toor, 
G. Hennemann and R. Docter 
Abstract 
Tracer thyroxine (T 4), 3,3' ,5-triiodothyronine (T 3) and 3,3' ,5' -triiodothyronine 
(rT3) kinetic studies were performed in normal T4 substituted subjects before 
and during oral d-propranolol treatment, to determine whether changes in 
thyroid hormone metabolism in a propranolol-induced low T 3 syndrome result 
from inhibition of 5'-deiodination or inhibition of transport of iodothyronines 
into tissues. Data were analyzed according to a three compartmental model 
of distribution and metabolism. T 4 plasma appearance rate decreased by 16% 
(p < 0.01), reflecting a decreased intestinal absorption of orally administered 
T 4 during propranolol. Serum T 4 and free T 4 levels increased significantly by 
14%, while T4 metabolic clearance rate (MCR) was lowered by 26% (p < 0.001). 
No changes were observed in size of the three T4 compartments, or in the 
fractional and mass transfer rates of T 4 from plasma to the rapidly (REP) 
and slowly (SEP) equilibrating pools. Serum T3, free T3, T3 plasma pool, T3 
mass transfer rate to REP and SEP and the T3 pool masses were all significantly 
decreased during propranolol to a similar extent as the T 3 plasma production 
rate (PR). T3 MCR decreased by 14% (p < 0.05). Serum total and free rT3 
increased, while the rT3 MCR was substantially lowered during propranolol 
(p < 0.001). The rT3 plasma pool, rT3 REP,and SEP, and the mass transfer 
rates to REP and SEP increased, while no alterations were observed in rT3 
PR and fractional transfer rates of rT3 to REP and SEP. 
It is concluded that the d-propranolol induced changes in thyroid hormone 
metabolism, resulting in a low T3 syndrome, are due to inhibition of thyroid 
hormone deiodination. This is in contrast to the low T 3 syndrome during caloric 
deprivation, which results from inhibition of transport of iodothyronines into 
the liver. 
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Introduction 
A variety of factors lead to a low T 3 syndrome in man, e.g. caloric deprivation 
(35), non-thyroidal illness (6) administration of dexamethasone (8), propyl-
thiouracil (1 ,18), X-ray cholecystographic agents (7) and d,l-propranolol (37 ,39). 
In case of d,l-propranolol the induction of a low T 3 syndrome has been shown 
in normal persons, thyrotoxic and L-T4 substituted, hypothyroid patients (14). 
In this syndrome serum T 3 is lowered and rT 3 increased, due to a decrease 
in both production rate (PR) of T 3 and metabolic clearance rate (MCR) of 
rT3 (27,28). During d,l-propranolol these changes have been explained by the 
assumption of an inhibition of 5' -deiodinase in the liver by this compound. 
However, not in agreement with this seems the fact that the concentration 
of d,l-propranolol, which causes a 50 % inhibition of this enzyme (K) in vitro 
is about 0.5 mM (16), while therapeutic levels are much lower i.e. between 
0.5 and 1 uM in serum (30). On the other hand transport of iodothyronines 
into rat hepatocytes in primary culture was shown to be inhibited by propranolol 
in a concentration as low as 1 uM, with a concomitant lowering of the 
intracellular A TP concentration (24). Furthermore, we could recently indicate, 
using tracer kinetic studies and analysis of the plasma disappearance curves 
with a three compartmental model of distribution and metabolism (11,12), 
an inhibition of mass transfer of T4 into the rapidly equilibrating pool (REP) 
in obese man during caloric restriction. The REP is mainly composed of liver 
and kidney ( 11) and inhibition ofT 4 transport into the REP leads to a decreased 
substrate availability for T 3 production as part of the underlying mechanism 
in the low T3 syndrome in man during caloric deprivation (36). 
Because inhibition of transport of iodothyronines apparently offers an 
alternative or a<;lditional mechanism in eliciting a low T 3 syndrome, tracer 1' 4, 
T3 and rT3 kinetic studies were performed to investigate whether the low T3 
syndrome induced by propranolol is caused by a mass transfer inhibition of 
T4 and rT3 into the REP (liver), and/or by inhibition of conversion of T4 
to T3 and rT3 to Tz which reactions are both catalyzed by 5'-deiodinase. Studies 
were performed according to the three compartmental model of distribution 
and metabolism, as developed by DiStefano et al (11,12). We chose d-
propranolol as experimental drug because of its efficacy in inducing a low 
T3 syndrome in man (21) without having beta-blocking activity (31), which 
may complicate interpretation of the results. 
Materials and Methods 
Subjects 
Six normal, healthy male students, age 22-24 years, participated in this study. 
All had normal thyroid function as measured by total serum T 4, T 3-resin uptake 
and TSH response to an intravenous bolus of TRH. The study and protocols 
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were approved by the Ethical Committee of the medical center and informed 
consent was obtained from all participants. None of these volunteers had used 
any medication within three months of the study. All subjects had normal 
weight. During the study, subjects were kept on a normal, weight maintaining 
diet. L-thyroxine substitution (200 ug a day) was started five weeks before 
the first tracer study and continued throughout the total experimental period. 
5 Days after the end of the first measurement of thyroid hormone kinetics, 
an oral d-propranolol regimen of 80 mg t.i.d. was started and continued until 
the second thyroid hormone tracer kinetic experiments (which started when 
d-propranolol had been used for 14 days) were completed. Throughout the 
kinetic studies subjects were using Lugol's solution t.i.d. 10 drops, to prevent 
thyroidal uptake of radioactive iodide liberated after metabolism of the tracer. 
Methods 
1251-T4 and 1311-T3 were obtained and prepared, respectively, as described 
previously (36). 131I-rT3 was prepared in an essentially similar iodination 
procedure as described for 1311-TJ, with 3,3'-T2 as a substrate and using the 
chloramine-T method (20). 25 uCi 125I-T4 and 30 uCi 1311-rT3, were injected 
intravenously in 2 ml of 2% human serum albumin in phosphate buffered 
saline. Three days later 30 uCi 131I-T3 was given in a similar way. Blood samples 
were collected at 5, 10, 15, 30, 45 min, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 14 and 16 hours for rT3. For T3 the same time schedule 
was used extended with 24, 32, 48, 56 and 72 hours. For T4 the sampling 
schedule of TJ was used during the first 3 days, followed by one sample/ 
day during the following 6 days. Tracer T4 was isolated from serum by TeA-
precipitation, tracer T3 by adsorption of the iodothyronines to Sephadex G-
25 at high pH and subsequent elution of TJ with specific T3-antibodies (36). 
Tracer rT3 was isolated from serum by the same procedure utilizing rabbit 
anti-rT 3 antiserum instead of T 3 antiserum. Recovery of added labeled rT 3 
from serum samples was 96.9 ± 0.12% (mean± SD, n = 6). Further experimental 
conditions and procedures were essentially similar as have been described (36). 
Total and free hormone concentrations were measured in serum samples 
collected before, during and after the kinetic studies to ascertain that the kinetic 
studies were performed under steady state conditions. Free hormone concen-
trations were measured _by equilibrium dialysis (36). 
d-Propranolol tablets (40 mg) were obtained by a generous gift from ICI-
Farma, Holland B.V. (Mrs. Dr. R. Koster). 
Serum levels of propranolol were kindly determined by Mr. E. Vervloet, 
chemist, by high-performance liquid chromatography on a chiral phase column 
(38). 
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~ CR 5 ~ SR ~ CRf 
"slow"pool ~ plasmapool ~ "fast"pool 
03 ... 01 ~ Oz 
SEP kl3 kl2 REP 
J k03 J koz 
Ds= 03 x ko3 Df= Oz x koz 
Computable from blood-borne data 
-ku k21 + k31 > 0 cl kl2 X k21 > 0 
-k22 = kl2 + k02 > 0 cz kl3 X k31 > 0 
-k33 kl3 + k03 > 0 
Fig. 1. Three pool model of iodothyronine distribution and metabolism. The K;; values (i#j, 
i, j=1, 2, 3, all K;; >O) are fractional transport rates (hours-1) from pool j to pool i. K, 1, 
K22 and K33 are fractional turnover rates (hours-1 of pool Q,, pool 02 and pool Q3, respectively. 
The relations at the bottom are the combinations of these parameters computable from 
data obtained by blood sampling only. For a complete list of nomenclature see Glossary. 
For evaluation of the T.-model only secretion (SR) of T. into the plasma pool should be 
considered, while for evaluation of the T3-model also T3-production by conversion both in 
the slowly equilibrating pool (CRs) and in the rapidly equilibrating pool (CRF) should be taken 
into account. 
Calculations 
Serum radioactivity of each iodothyronine was expressed as percentage dose 
per liter. For each iodothyronine the change of the activity as percentage dose 
per liter as a function of time could be described as the sum of three exponentials 
as 
3 
y(t) = I, A;e-f..,t 
i=l 
where t is time, A; is the coefficient and A; is the constant of the exponent 
of the i-th exponential. A "peel-off' system of curve fitting was used, of which 
' pmcedure a detailed outline can be found in the legend of figure 2. Together 
with the parameters estimated by linear regression on the straight parts of 
the curve (figure 2) the standard deviations of these parameters were calculated 
too. Finally it was determined whether the estimated parameters were signi-
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Fig. 2. Typical example of the curve fitting of a T4-disappearance curve by a three exponent 
model. Panel A: plot of log y, (in % Oose/1) against time, with the least squares regression 
line on the final straight part of the curve, giving estimates of coefficient A, 7.87 (± .23 
(SO)) %0/l and exponent A., .0029 (± .0002) hour-1. Panel 8: plot of log (y(t)-A,e-"-•1) against 
time, with the least squares regression line on the straight part of the curve, giving estimates 
of coefficient A2 2.68 (± .22) %0/L and exponent A.z0.031 (± .004) hour-1 Panel C: plot 
of log (y(t)-Aze-M-A3e-"-3t) against time, giving estimates of coefficients A1 14.88 (± 1.19) 
%0/L and exponent A.1 0.80 (± 0.04) hou(1. MCR=0.86 1/day; Vplasma=3.9 I; residual 
sum of squares= 39, total sum of squares = 7286. 
ficantly different from zero. From the Ai and Ai thus obtained, the parameters 
as depicted in Figure 1 of a three pool model of iodothyronine- distribution 
and metabolism ( 11) could be calculated as has been outlined in detail elsewhere 
(36). Rearrangement of these terms gives the following formula for K21 
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Table 1. Upper and lower values for K21 (fractional transfer rate from 
plasma to the REP). 
Control period 
K21 T4 T3 rT3 
h-1 h-1 h-1 
lowest value 0.51 (0.06) 1.34 (0.17) 0.81 (0.03) 
highest value 0.52 (0.06) 1.53 (0.17) 2.59 (0.09) 
difference 2.8% (0.3) 14.0% (1.5) 104.6 % (3.3) 
During propranolol treatment 
K21 T4 T3 rT3 
h-1 h-=-1 h-1 
lowest value 0.52 (0.08) 1.11 (0.26) 1.60 (0.28) 
highest value 0.53 (0.09) 1.28 (0.25) 2.46 (0.30) 
difference 2.0% (0.3) 14.6% (4.0) 43.1 % (9.4) 
mean (SEM) (n=6) 
A minimal value of K21 can be found if Koz = 0, i.e. no disposal in the rapidly 
equilibrating pool (REP). K21 is maximal if Ko3 = 0, i.e. no disposal in the 
slowly equilibrating pool (SEP). If K21 is known, all other parameters can 
be calculated. 
Results 
Figure 2 shows a typical example of a three exponential curve fit_ of the plasma 
disappearance of T4. As can be seen in the legend the fitted A; and ; (i=l,3) 
are highly significantly different from zero, indicating that a three exponential 
curve fit is valid. In this way the plasma disappearance curves of T 4, T 3 and 
rT3 in all subjects before and during propranolol were best described as the 
sum of three exponentials, with all A and A; significantly (p < 0.01 or better) 
different from zero. 
In table 1 and figure 3 the minimal and maximal values of Kz1 and K31 
for the T 4, T 3 and rT 3 models are shown, both before and during propranolol 
treatment (table 1). The difference between the maximal and minimal value 
of Kz1 for T4 and T3, respectively, is small. Therefore the mean values of Kzt 
were used to calculate all other parameters. This maneuver will divide the 
disposal of T3 and T4 equally between the REP and the SEP, although no 
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Fig. 3. Relationship of the fractional transfer rate constant from plasma to the rapidly 
equilibrating pool (K2d and to the slowly equilibrating pool (K3J) on the disposal rate from 
the rapidly equilibrating pool, for T., T3 and rT3. As the fractional disposals from the rapidly 
and slowly equilibrating pools are inversely related (the sum of both being 1 ), the relationship 
between K2r or K3r and the disposal from the slowly equilibrating pool will be inverse. 
data exist that this is actually the case in vivo. There is a great difference, 
however, between the minimal and maximal value of K21 for rT3 and therefore 
the mean value can not be used for calculation of kinetics. Fortunately, however, 
more data are available for rT3 as to the site where the disposal actually takes 
place. rT3 clearance is markedly reduced in liver cirrhosis (10) and in subjects 
treated with PTU (32) which inhibits type I 5' -deiodinase which is mainly located 
in the liver (26). Recently it has been found (3) by direct blood sampling in 
the hepatic vein and artery in humans that the clearance of rT3 by the liver 
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is equal to the total body removal of this hormone. Because of these notions 
and the fact that the liver is part of the REP ( 11 ), we located the disposal 
of rT3 in the REP and therefore used the highest value for K21 to calculate 
all other parameters for rT3. 
A summary of the results thus obtained can be found in table 2. T4 plasma 
appearance (production) rate decreased by 16% during propranolol as compared 
to control. The total serum T4 concentration increased by 14%, with a similar 
increase of the free hormone level. T4-MCR decreased by 26%. No changes 
were observed in size and pool of the three T 4 compartments, except a 23 
% increase of the REP. No alterations in fractional transfer rate of T4 to the 
REP or SEP could be detected. 
In all subjects a low T 3 syndrome was induced by administration of d-
propranolol. Total serum T3 levels decreased by 29%, while those of total 
rT3 rose by 158%. T3 production rate and MCR decreased by 38% and 14% 
respectively. Serum total and free T3, the three T3 pools, mass transfer rates 
to the REP and the SEP were all decreased to a similar extent as the production 
rate. 
Serum total and free rT3 and plasma pool were elevated, MCR was much 
lower, while the production rate did not change. Propranolol did not induce 
alterations in sizes (in liters) and fractional transfer rates of rT 3 with regard 
to the REP and the SEP. Pools and mass transfer rates increased to a similar 
extent as the plasma rT 3 concentration. 
Table 3 shows the model values which will change when the T4 or the T3 
models are recalculated with the disposal located in the SEP. In table 4 the 
same values are summarized, after recalculation of the models with the disposal 
located in the REP. From comparison of table 3 and 4 with table 2 it can 
be concluded that the findings summarized in the previous paragraphs are 
in no way dependent on the site were the disposal actually takes place. 
Propranolol levels 
Serum d-propranolollevels ranged from 0.14 uM to 0.70 uM. No laevo- isomer 
could be detected in the serum of the participating subjects. During the control 
period and d-;-propranolol administration, blood pressure and heart rate were 
frequently measured. No differences were observed between these two periods. 
Electrocardiograms obtained in both periods were similar. No side effects were 
reported during the 23 days of oral administration of 3 times 80 mg daily 
of d-propranolol. No significant change in body weight was observed during 
the total study period. 
54 
Table 2. T4, T3 and rT3 kinetics before and during propranolol treatment in six T4 substituted normals. 
Mean CONTROL d-PROPRANOLOL 
(SEM) 
T4 T3 rT3 T4 T3 rT3 
Production rate nmol/d 149.5 (8.14) 66.8 (3.6) 67.0 (7.0) 126 (8.0)" 41.2 (3.5)b 69.4 (3.3) 
MCR 1/d 1.53(0.08) 37.2 (1.7) 203.6 (5.6) 1.13(0.09). 32.1 (1.6)e 84.0 (6.7)a 
Plasma compartment 
free hormone cone. pmol/1 25.2 (0.8) 5.3 (0.1) 0.29(0.01) 28.6 (0.9)" 3.9 (0.06)" 0. 77 (0.02). 
total hormone cone. nmol/1 99.3 (7.7) 1.8 (0.07) 0.33(0.03) 113 (7.1 )b 1.28 (0.07)" 0.85 (0.07)" 
size I 4.7 (0.24) 8.2 (0.34) 4.3 (0.25) 4.5 (0.21) 8.0 (0.40) 4.1 (0.10) 
pool nmol 463 (41.6) 14.7 (0.8) 1.43(0.18) 510 (38.3) 10.2 (0.5)b 3.4 (0.28)" 
Rapidly equilibrating compartment 
size I 6.8 (0.71) 4.7 (0.4) 12.6 (2.3) 7.3 (0.66) 4.7 (0.3) 14.6 ( 1.1) 
Vl pool nmol 661 (69.3) 8.3 (0.6) 4.4 ( 1 0 11 ) 814 (69.7)d 6.0 (0.3)d 12.2 ( 1 .1 )b Vl 
mass transfer rate 
from plasma nmol/h 229 (19.3) 20.7 (1.8) 3.9 (0.44) 266 (16.0) 12.2 (1.3)" 8.4 (0. 7)" 
fractional transfer 
rate from plasma h-I 0.51 (0.06) 1.43 (0.17) 2.8 (0.31) 0.53(0.04) 1.19 (0.10)" 2.5 (0.1) 
Slowly equilibrating compartment 
size I 3.5 (0.16) 43.1 (5.0) 25.2 (3.2) 2.6 (0.37) 42.5 (5.0) 24.4 (1.5) 
pool nmol 341 (26.8) 76.7 (7.6) 8.4 (1.4) 302 (53.7) 53.7 (5.9)b 20.6 (1.8)b 
mass transfer rate 
from plasma nmol/h 15.8 (3.4) 7.5 (0.5) 0.44(0.10) 7.5 (0.95) 5.0 (0.43)" 1.28 (0.19)d 
fractional transfer 
rate from plasma h-1 0.037 (0.01) 0.51 (0.03) 0.35 (0.10) 0.015(0.002) 0.49 (0.02) 0.37 (0.03) 
•: p<0.001; b: p<0.005; c: p<0.01; d: p<0.025; •: p<0.05 (paired t-test; n=6) 
Table 3. T4 and TJ kinetics before and during propranolol treatment in six T4 substituted normals. 
Values were calculated with K21 minimal, i.e. with the disposal located in th~ slowly equilibrating pool. 
Mean CONTROL d-PROPRANOLOL 
(SEM) 
T4 T3 T4 T3 
Rapidly equilibrating compartment 
size I 6.7 (0.71) 4.4 (0.4) 7.3 (0.65) 4.4 (0.3) 
pool nmol 654 (68.6) 7.8 (0.6) 808 (69.2)d 5.6 (0.3)d 
mass transfer rate 
from plasma nmollh 227 (19.2) 19.5 (1.8) 264 (15.9) 11.5 (1.3)" 
fractional transfer 
rate from plasma h-1 0.51 (0.06) 1.36 (0.17) 0.53 (0.03) 1.13 (0.10)e 
Ul 
a, 
Slowly equilibrating compartment 
size I 4.1 (0.19) 49.6 (5.7) 3.3 (0.45) 48.3 (5.3) 
pool nmol 408 (29.0) 88.2 (8.8) 387 (64.5) 61.1 (6.2)b 
mass transfer rate 
from plasma nmol/h 18.3- (3.3) 8.6 (0.5) 9.6 (1.00) 5.7 (0.46)" 
fractional transfer 
rate from plasma h-1 0.042(0.01) 0.58 (0.03) 0.019(0.002) 0.55 (0.02) 
•: p<0.001; b: p<0.005; c: p<0.01; d: p<0.025; e: p<0.05 
(paired t-test; n=6) 
Vl 
-..l 
Table 4. T4 and T3 kinetics before and during propranolol treatment in six T4 substituted normals. 
Values were calculated with the K21 maximal, i.e. with the disposal located in the rapidly equilibrating 
pool. 
Mean CONTROL d-PROPRANOLOL 
(SEM) 
T4 T3 T4 T3 
Rapidly equilibrating compartment 
size I 6.8 (0.71) 4.9 (0.4) 7.4 (0.66) 5.0 (0.3) 
pool nmol 669 (70.0) 8.8 (0.6) 821 (70.2)d 6.3 (0.3)d 
mass transfer rate 
from-plasma nmol/h 232 (19.3) 21.8 (1.8) 269 (16.1) 12.9 (1.3)' 
fractional transfer 
rate from plasma . h-1 0.52 (0.06) 1.51 (0.17) 0.53 (0.03) 1.26 (0.10)" 
Slowly equilibrating compartment 
size I 2.8 (0.24) 36.6 (4.3) 1.7 (0.31) 36.8 (4.8) 
pool nmol 276 (29.6) 65.2 (6.6) 218 (44.7) 46.4 (5.6)b 
mass transfer rate 
from plasma nmol/h 13.3 (3.4) 6.4 (0.4) 5.4 (0.92) 4.3 (0.40)b 
fractional transfer 
rate from plasma h-1 0.031 (0.01) 0.43 (0.03) 0.011 (0.002) 0.42 (0.02) 
•: p<0.001; b: p<0.005; c: p<0.01; d: p<0.025; e: p<0.05 
(paired t-test; n=6) 
Discussion 
During propranolol treatment T4 plasma appearance rate decreased by 16%. 
Lumholtz et al (27,28) already suggested thatadministration of d,l-propranolol, 
reduces intestinal absorption of L-thyroxine in substituted hypothyroid patients. 
However, in our subjects with intact thyroid this conclusion is less secure, 
since there is a possibility that propranolol could have an effect on thyroidal 
secretion ofT 4 not suppressed by exogenous T 4· This effect cannot be mediated 
by beta-blocking activity because d-propranolol which was used in this study 
is devoid of this activity. Lumholtz et al (27,28), however, did not observe 
a rise in serum T 4 concentration, in contrast to the 14% rise in both total 
T4 and free T4 serum concentrations occurring in our patients. Others (39) 
also noticed a rise in total serum T4 during propranolol treatment. In concert 
with Lumholtz et al (27), T4 MCR was reduced during propranolol. A reduction 
of 26% in the T4 MCR only partially counter-effected by a 16% decrease in 
plasma production could explain an increase in both total T4 and free T4 serum 
levels as observed in this study. A decrease in production rate ofT3 and metabolic 
clearance rate of rT3 can (see also introduction) result from inhibition of 5'-
deiodinase and/or transmembraneous transport of iodothyronines (i.e. T4 and 
rT3) into the liver. Current thinking places the liver in a dominant role in 
both T3 production and rT3 degradation. This notion results from the ob-
servation that inhibition of type I 5'-deiodinase (which is quantitatively most 
abundant in the liver (26)) by propylthiouracil, induces a 50-75% decrease 
in serum T 3 concentration in thyroidectomized L-thyroxine substituted rats 
(4,33)., In addition, the net removal of rT3 by the human liver equals the total 
body removal (3). From these studies it was also conciuded that the liver probably 
does not contribute to plasma rT 3· This conclusion is substantiated by the 
fact that rT 3 could not be detected in the perfusate of T 4 perfused rat livers 
(23), or in incubation media of rat liver slices (2) and cultured rat hepatocytes 
(29) incubated with T4. Further support is obtained by the finding of a similar 
production rate of rT3 in propylthiouracil and methimazole (which does not 
inhibit type I deiodinase) treated hyperthyroid patients (25). The observation 
of an unchanged (or even increased) pool of T4 and rT3 in the REP (which 
contains liver and kidney (11,12)) indicates that limited substrate availability 
to 5'- deiodinase can not explain the diminished T3 production and rT3 MCR 
reported in this study. Our findings only support an inhibition of deiodination 
by propranolol or a metabolite thereof. Because a considerable amount of 
T 3 is metabolized outside the liver and, as mentioned above, the liver does 
not contribute to plasma rT3, no conclusion can be drawn with regard to a 
possible effect of D- propranolol on liver 5-deiodination, while there seems 
to be no effect on 5-deiodinase in tissues outside the liver, because rT 3 production 
and T3 MCR are unaltered (table 2) during propranolol treatment (and both 
rT3 production and T3 deiodination are 5-deiodination reactions). 
As can be calculated from table 2, no change was found in the fraction 
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of T4 disposal which was degraded via the deiodinative route (T4 into T3 and 
rT3 before and during propranolol, 89% and 88% respectively). Therefore, a 
d-propranolol-induced inhibition of T4 to T3 conversion does not result in 
an increased T4 degradation through non-deiodinative pathways as has been 
found during d,l-propranolol administration (9,28). In our study however, it 
can be calculated from table.2 that d-propranolol induced a shift in T 4 conversion 
away from T3 and towards rT3. Thus, before propranolol T4 was equally 
converted i.e. 45% both to T3 and rT3. During propranolol the percentages 
were 33% and 55% respectively. By comparison of the data shown in table 
3 and 4 with those presented in table 2 it can be concluded that the site where 
the disposal actually takes place is irrelevant. Whether the data of table 4 
(disposal from the REP), table 2 (disposal equally divided between REP and 
SEP) or table 3 (disposal from the SEP) are used, the same conclusions have 
to be drawn with respect to the changes in metabolism and distribution of 
T 4 and T 3 induced by propranolol. Shifting the disposal from the REP to 
the SEP has only a minimal effect on the data concerning the REP, while 
the influence on the absolute value of the data of the SEP is moderate ( about 
30 % change), however the relative changes of the data before and during 
propranolol are not affected in any way. 
We found a mean plasma compartment size of 4.7 1 for T4, 4.3 1 for rT3, 
which values are comparable, and 8.2 1 for T3, which value is much larger 
(table 2). On first thought one would expect similar values for the three 
hormones, however beside plasma this compartment also contains blood cells, 
and we have shown (13) that erythrocytes contain a carrier mediated uptake 
system for at least T 3· Therefore we have to take into account uptake of hormones 
by these blood cells. Consequently the measured volume of the accessible 
(plasma) compartment is the sum of the plasma volume and the plasma 
equivalent volume of the hormone bound by the blood cells. Even if there 
exists a comparable uptake mechanism for T4 and rT3 as for T3, uptake of 
T 3 into for instance erythrocytes will be more pronounced than uptake of the 
other hormones, because the free fraction of T 3 in plasma is about ten times 
larger than that of T4 or rT3. This will lead to a relative higher proportion 
of T3 bound to erythrocytes, and thus to a larger plasma volume measured. 
The question remains as to how propranolol induces its effects on liver 5'-
deiodinase. In vitro experiments revealed a K; of d,l- propranolol on this enzyme 
of about 0.5 mM (16), which is three orders of magnitude higher than therapeutic 
levels in man (30). In vivo experiments show that dog liver (19) and rat liver 
(5,34) in contrast to some other tissues, do not accumulate propranolol relative 
to plasma. Actually, rat liver showed the lowest tissue concentration of 
propranolol after intravenous injection of the following tissues tested: adipose 
tissue, lung, brain, heart and muscle (5). Determination of the subcellular 
distribution of propranolol-binding in liver, revealed that mitochondrial and 
microsomal fractions contained the highest concentration of propranolol, both 
after administration of the drug in vivo and after incubation with homogenates. 
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5'-Deiodinase activity is localized in the microsomal fraction (15). No data, 
however, exist as to biopsy measured hepatic accumulation of propranolol 
in human liver. 4-0H-propranolol, a metabolite with equipotent beta blocking 
activity in comparison to the parent compound, has been shown to markedly 
inhibit 5'-deiodinase activity, at concentrations between 34-80 uM (22). However 
only 10% of administered propranolol is converted to 4-0H-propranolol and 
therefore plasma concentrations are below 50 nM (22), which makes this 
compound an unlikely candidate for the inhibition of the enzyme. Furthermore, 
in rats hepatic accumulation (50 times) of an (undefined i.e. not being 4-0H-
propranolol) metabolite of propranolol relative to plasma was demonstrated 
after chronic oral and subcutaneous administration of propranolol, in contrast 
to the parent compound ( 17). The_se data point to the possibility of a metabolite 
rather than propranolol itself affecting 5'-deiodinase. Of course another 
explanation for the disparity between the K; of propranolol for inhibition of 
5'-deiodinase and therapeutical serum levels in man may be that the estimated 
K; is not the true value of the pure enzyme or the enzyme as it operates in 
vivo. 
In summary, from our here reported kinetic data, it can be concluded that 
the d-propranolol-induced low T 3 syndrome results from inhibition of thyroid 
hormone deiodination. This is in contrast to the low T 3 syndrome caused by 
caloric deprivation, in which we recently (36) could indicate inhibition of 
transmembraneous transport of iodothyronines as the principal underlying 
mechanism. It seems therefore possible that a low T 3 syndrome may result 
from different mechanisms. 
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CHAPTER4 
EARLY SERUM DISAPPEARANCE AND COMPUTED LIVER 
UPTAKE OF THYROXINE IN HUMANS DURING CALORIC 
DEPRIVATION, D-PROPRANOLOL ADMINISTRATION AND 
AFTER FRUCTOSE 
Hans van der Heyden, Roelof Docter, Hans van Toor, 
Eric P. Krenning and Georg Hennemann 
Abstract 
Inhibition of transmembraneous transport of iodothyronines has been proposed 
as the underlying mechanism in inducing the low T3 syndrome in man during 
caloric restriction. Propranolol, however, elicits a low T3 syndrome in man 
by inhibition of thyroid hormone deiodination. Transport of thyroid hormones 
into cells has, in vitro, been shown to be ATP dependent. We studied T4 serum 
tracer disappearance curves in a group of 4 obese subjects before and during 
caloric restriction and after intravenous fructose loading. Similar kinetic studies 
were also performed before and during an oral regimen of 3 times 80 mg 
D- propranolol in 6 T4-treated normal subjects. In addition, computed T4 hepatic 
uptake was determined during these conditions in both groups. 
Intravenous fructose administration induced a rise in serum lactic acid and 
uric acid, indicating a decrease in liver A TP. This was observed in concomitance 
with a decreased serum tracer T4 disappearance and computed T4 uptake in 
the liver. These results suggest ATP-dependency of transport of iodothyronines 
into the liver in vivo. Caloric restriction also resulted in a slowing down of 
the T 4 serum disappearance and a decrease of liver uptake of T 4, pointing 
to an inhibition of transmembraneous transport of iodothyronines in this 
condition as well. In contrast, D-propranolol administration did not change 
T4 serum disappearance and computed T4 hepatic uptake. These latter findings 
are in agreement with previous observations that D- propranolol induces a 
low T3 syndrome by inhibition of deiodination ofiodothyronines. It is therefore 
concluded that the low T 3 syndrome in man can result from, at least two 
different mechanisms i.e. either by decreased transport ofT 4 into T 3 generating 
(e.g. liver) tissues or by attenuated deiodination of T4 into T3. 
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Introduction 
The low T 3 syndrome is characterised by a lowered serum T 3 level in 
concomitance with an increased serum rT 3 level, due to a decrease in T 3 
production rate and rT3 metabolic clearance rate, respectively. A variety of 
factors lead to a low T 3 syndrome: caloric deprivation ( 1 ,2), non-thyroidal 
illness (3), administration of propranolol (4), dexamethasone (5,6), propyl-
thiouracil (PTU) (7,8) and X-ray cholecystographic agents (9,10,11). Studies 
in rat liver homogenates from starved rats (12) or from rats treated with PTU 
(13), dexamethasone (14) or propranolol (15) revealed a decreased 5'- deiodinase 
activity. It was therefore suggested that inhibition of this deiodinative step 
was responsible for the observed changes in serum iodothyronines as seen in 
the low T 3-syndrome. An alternative explanation, however, was given by 
Krenning et al (16), who showed in rat hepatocytes in primary culture that 
iodothyronines were taken up by an active, A TP dependent, transport me-
chanism, by which T4 and rT3 enter the cell via a common pathway that is 
different from that of T 3· Inhibition of notably the T 4-rT 3 transport pathway 
to tissues would result in an increased serum rT 3 concentration and decreased 
serum T3 due to reduced intracellular T4 availability for conversion to T3. 
The liver plays a dominant role in T3 production and rT3 metabolic clearance 
(see discussion section). To study mechanisms further that are operative in 
the observed changes in T3 and rT3 kinetics in the low T3 syndrome, early 
T 4 tracer disappearance from serum (representing transport into the liver; see 
discussion) was examined in obese humans in three conditions: during a weight· 
maintaining diet and during fasting and after an intravenous bolus of fructose 
which induces a prompt and significant fall in liver ATP (17,18). Furthermore, 
T4-tracer disappearance was measured in a group of T4 substituted normal 
subjects before and during administration of D-propranolol. In addition uptake 
in the liver was computed, using the parameters found with a three compart-
mental model of thyroid hormone distribution and metabolism (19,23). 
Glossary 
(i = 1,2,3; j = 1,2,3; i #- j) 
t Time (min) 
y(t) Plasma activity at timet(% dose/L) 
A Coefficient of the ith exponential component(% dose) 
A; Exponent of the ith exponential component (min-1) 
Q1 Size of pooll (plasma pool;% dose) 
Q2 Size of pool 2 (fast or rapidly equilibrating pool;% dose) 
Q3 Size of pool 3 (slow or slowly equilibrating pool;% dose) 
k;i Fractional transport rate from pool j to pool i (min -l) 
ko; Fractional disposal rate in pool i (min -1) 
Vp Plasma volume (L) 
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Subjects and methods 
Subjects 
Four (three women), otherwise healthy, obese subjects, age 27-36 years (mean 
30.8 years) participated in this study. All had normal· thyroid function as 
measured by serum T 4, T 3-resin uptake and thyrotropin response to an 
intravenous bolus of thyrotropin releasing hormone. None of the persons used 
or had recently (within three months) used any medication. At the start of 
the study, body weight ranged from 96-117 kg(mean 108.25 kg). All subjects 
had at least 30% overweight according to the monograph method for assessing 
body weight as described by Thomas et al (20), range 32-91% (mean 61.5%). 
Serum T 4 tracer studies were performed three times. First during a control 
period, while patients were kept on a normal weight-maintaining diet. The 
study was then repeated after one month. The only difference with the control 
study was an intravenous fructose loading of0.5 g/kg(administered in 20 minutes 
· as 20% (w/v) solution) immediately in advance of the injection of the tracer. 
In the control and fasting (see below) period an equal volume of saline was 
similarly given. One month after the second study, the third study was done 
when the subjects were on a 240 kcal ModifastR diet for seven days. This 
diet contains: 33 g protein, 25.5 g carbohydrate and 0.7 g fat and adequate 
supplies of water, minerals and vitamines. 
We also analyzed early serum T 4 tracer kinetics performed in six normal 
males, age 22-24 years, before (control) and during the use of D-propranolol 
80 mg t.i.d .. These studies were primarily intended to elucidate the underlying 
mechanism by which D-propranolol induces a low T 3 syndrome. The results 
of all other kinetic data in these subjects have been reported elsewhere (21). 
These six pers.ons were euthyroid and had normal thyroid function as defined 
above. They were put on !-thyroxine treatment (200 ug daily) 5 weeks before 
the control tracer study and T 4 treatment was continued until the end of the 
two kinetic studies. D-propranolol was started 14 days before the second study. 
T 4 substitution was given to suppress thyroidal T 3 secretion rendering calculation 
ofT4 into T3 production easier (see 21). The studies and protocols were approved 
by the Ethical Committee of the medical centre and informed consent was 
obtained from all participants. 
Materials, preparations and calculations 
131I-T4 was prepared by iodination of 3,5,3'-T3 with 131I by the chloramine-
T method (22) .. Iodination was performed by mixing 10 ul volumes of Na 
131 I, 0.5 M sodium phosphate buffer pH 7.5, 3,5,3'-T3 (1 ug/ul in 0.05 M sodium 
phosphate buffer pH 7 .5) and chloramine-T (1 ug/ul in 0.05 M sodium phosphate 
buffer pH 7.5), in that order. The reaction was terminated after one minute 
by adding 100 ml sodium bisulfite (1 mg/ml in 0.05 sodium phosphate buffer 
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pH 7.5). The reaction mixture was applied on a small (10 x 0.5 em) Sephadex 
LH-20 column and eluted with 30% ethanol in 0.05 M sodium carbonate pH 
11.5 (v/v). T4 fractions were pooled and evaporated to dryness under a stream 
of nitrogen. Fifty microcurie 131!-L-thyroxine in 1,5 ml of 2% human albumin 
in phosphate buffered saline, were administered to the patients via an intra-
venously inserted canula in the arm. Through a catheter in the contralateral 
arm, blood samples were drawn at regular intervals for determination of 
radioactivity. 
N a 131! forlabeling of3,5,3 '-T 3 was purchased from The Radiochemical Centre, 
Amersham, U.K.. All other reagents used were of the highest purity available. 
Percent tracer dose at the different time intervals and serum levels of T4, 
free T4 (dialysis), T3 and rT3 were determined as outlined previously (23). D-
propranolol tablets (40 mg) were obtained by a generous gift from ICI-Farma, 
Holland B.V .. 
Uptake of tracer T4 into the rapidly equilibrating compartment (REP) (see 
discussion) was calculated using a three compartmental model of thyroid 
hormone distribution and metabolism (19), applied by us in humans as reported 
in an other study (23). During the first six hours after tracer injection integrated 
influx of tracer T 4 into REP minus efflux from REP was computed representing 
net uptake in this compartment (see appendix). 
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Fig. 1. Serum lactic acid and uric acid levels after i.v. fructose in 4 obese subjects. 
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Results 
In the control and fructose periods, during whlch the obese subjects were kept 
on a weight-maintaining diet, no change in body weight occured. Serum levels 
of T4, T3 and rT3 were normal at the time of kinetic studies in both periods. 
During the period of caloric restriction a mean reduction in body weight of 
6.23% (± 0.61 SD) was observed. Although serum T4 remained normal (mean 
± SD) 86.0 ± 4.83 nmol/1, serum T3 was below normal due to caloric restriction: 
0.74 ± 0.05 (normal range 1.1 - 3.1 nmol/1) and rT3 was elevated: 0.56 ± 
0.045 (normal range 0.12- 0.45 nmol/1). 
Figure 1 shows mean serum levels of uric acid and lactic acid after intravenous 
fructose administration. A clear rise of both was achieved. 
Figure 2 gives the mean decline in serum tracer T4 expressed as percentage 
of the dose injected until six hours after injection. It can clearly be seen that 
% dosis in 
plasma pool 
100 
50 
0 
0 100 
£ control 
· .- fructose 
• cal.dep. 
200 
time (min) 
0.01 < p < 0.025 
p < 0.001 
300 
Fig. 2. Early serum tracer T. disappearance before and during caloric deprivation (cal. dep.) 
and after i.v. fructose in 4 obese subjects. 
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Fig. 3. Computed tracer T. uptake in REP before and during caloric deprivation (cal. dep.) 
and after i.v. fructose in 4 obese subjects. 
T4 tracer disappears more slowly from the plasma compartment during caloric 
deprivation and after fructose administration (paired-t-test, p<O.OO 1 and 
p<0.025 respectively) as compared to control. 
Figure 3 summarizes the computed uptake of T4 in the rapid equilibrating 
pool, mainly composed of the liver (23), during caloric restriction and after 
fructose. In both conditions a significant decrease in initial hepatic uptake 
was found as compared to control (paired t-test p<0.025 for fructose and 
p<O.OOl for caloric deprivation). 
In figures 4 and 5, T4 serum disappearance curves and computed T4 hepatic 
uptake curves respectively in the normal T 4 treated males during the control 
and D-propranolol treatment are shown. A paired-t- test showed a significant 
increased hepatic uptake during propranolol while serum disappearance rates 
were not different. 
All six participants developed a low T3 syndrome during D-propranolol; 
serum T3 1.28 ± 0.07 nmol/1 vs control 1.8 ± 0.07 nmol/1 (p<O.OOl) and 
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% dosis in 
plasma pool 
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50 
"" control 
• propranolol 
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0 100 200 
time (min) 
300 
Fig. 4. Early serum tracer r. disappearance before and during propranolol administration 
in 6 normals treated with T •. 
serum rT3 0.85 ± 0.07 nmol/1 vs 0.33 ± o:o3 nmol/1) (p<O.OOl). The serum 
free T4 concentration was significantly increased; 28.6 ± 0.9 pmol/1 vs control 
25.2 ± 0.8 pmol/1 (p<O.Ol). 
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Fig. 5. Computed tracer T4 uptake in j'lEP .before and during propranolol administration in 
6 normals treated with T4. 
Discussion 
T 4-tracer serum disappearance curves of each subject in each condition could 
be fitted to the sum of 3 exponentials, indicating a three compartmental 
distribution of thyroxine, i.e. a plasma pool, a rapidly equilibrating pool (REP) 
and a slowly equilibrating pool (SEP) (19). 
Several studies (24,25,26) show time differences between various tissues for 
equilibration with serum radioactive thyroid hormone. Sheep, closely resembling 
man with respect to thyroid hormone metabolism and serum thyroid hormone 
binding proteins, show equilibrium of liver, kidney and lung with serum tracer 
thyroid hormone within 1-2 hours after injection while in intestine, heart and 
salivary glands equilibrium was reached after 4 hours. Brain, skin and muscle 
equilibrated after 32-60 hours. In man a marked difference between liver and 
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forearm was found (24). Several studies (27,28) showed equilibrium of radio-
activity above the liver with serum T4 tracer after 2-4 hours. Although including 
kidneys and lungs, the REP is predominantly constituted by the liver (23,26,29) 
which contains about 113 of the total body T4 pool (30). Current thinking 
places the liver in a dominant role in both T3 production and rT3 degradation 
(23,31). These processes are greatly influenced if passage of thyroid hormones 
into tissues is suppressed by inhibition of transport over the cell membrane 
(16). Inhibition of the active transport system of T4 and rT3 into the liver 
results in changes in serum thyroid hormones as seen in the low T3 syndrome 
(23). Because equilibrium of tracer T4 between plasma and liver compartment 
will be reached between 2-4 hours (27,28) and since the liver is regarded as 
a most important organ with respect to T3 production from T4, we examined 
the T 4 serum tracer disappearance curve during the first 6 hours after injection. 
From figure 1 it can be seen that intravenous fructose administration induces 
a prompt rise in lactic and uric acid, reflecting a marked decrease in liver 
ATP concentration (17,18). No changes were observed in serum total and free 
T4 (not depicted). Figure 2 gives the mean serum T4 tracer disappearance curve 
after fructose injection. The tracer disappears more slowly than in the control 
period (paired-t- test p<0.01), indicating an inhibition of egress from the plasma 
compartment. Our data suggest that this inhibition of egress from plasma results 
from a decreased uptake of T 4 by the liver due to ATP depletion as has been 
shown in rat hepatocytes in primary culture (16). 
Caloric restriction resulted in an even more pronounced inhibition of T 4-
tracer egress from plasma. This phenomenon was observed, despite a markedly 
increased free hormone level, due to a rise in the free fraction. It is, however, 
not known if caloric restriction induces a decrease in cellular A TP concentration 
in man. In 48 hour fasted rats we found a decreased liver A TP when chemically 
measured (van der Heyden et al, to be published}, as others found when 
determined by 31P-NMR spectroscopy (32). It has also been suggested (33) 
that microheterogeneity of A TP distribution can occur during fasting in cells 
without membrane compartmentation due to nonuniform distribution of ATP-
generating and ATP consuming systems. This phenomenon may lead to 
diminished ATP concentration in the area of the plasma membrane, which 
decrease may not always be apparent when total cellular A TP is being considered. 
An other factor for inhibition of transmembraneous transport of iodothyronines 
has recently been shown by Krenning et al (34). From the work of Chopra 
et al (35,36) it became evident that sera of patients with non-thyroidal illness 
and low serum T4 may contain an inhibitor of thyroid hormone binding to 
serum proteins. Krenning et al (34) showed that sera of patients with non-
thyroidal illness and a low T 4 state, inhibit thyroid hormone uptake by 
hepatocytes in primary culture without a direct effect on deiodination. Although 
the exact nature of the inhibitor is not known, many arguments are in favour 
that it might belong to the group of fatty acids, which are known to increase 
during fasting. Fatty acids modulate the fluidity and negative surface charges 
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of cell membranes (37 ,38) and it is conceivable that transmembraneous transport 
of iodothyronines is inhibited in this way. 
We could recently indicate transport inhibition of iodothyronines as a major 
underlying cause for inducing the changes in serum thyroid hormones as seen 
in the low T3 syndrome during caloric deprivation (23). The here reported 
decreased disappearance ofT 4-tracer from serum in caloric restriction and after 
fructose is compatible with the same phenomena. We also computed the uptake 
of the percentage of the tracer dose injected, in the REP according to the 
three compartmental model of thyroid hormone distribution and metabolism 
which we used previously (23). Figure 3 shows that during caloric deprivation 
and after fructose injection, the uptake of the injected T4 tracer in the REP 
(mainly representing the liver) is indeed diminished. The slowest disappearance 
of T 4 from serum, i.e. caloric restriction, is reflected by the most pronounced 
inhibition ofT 4 uptake in the rapidly equilibrating pool. Computed liver uptake 
in the control period starts to decrease soon after the maximum value has 
been reached so that at appr. 250 min. it is not different anymore from liver 
uptake in the fructose experiment. 
We also analyzed non-published data from our experiments in normal T 4 
treated males before and during D-propranolol in which propranolol induced 
a low T3 syndrome. No changes in serum T4 disappearance was seen (fig.4). 
Uptake of T4 into the liver (rapidly equilibrating pool) was even increased 
probably related to the increased serum free T4 concentration. Thus in this 
situation of the low T3 syndrome no transport inhibition of T4 into the liver 
was found. We could indeed attribute the low T3 production due to propranolol 
to diminished T4 into T3 deiodination (21). 
Appendix 
Calculation of the uptake in the rapidly equilibrating pool (REP). The following 
set of equations was used: 
%Dit plasma I 
%D/t REP II 
%Dit SEP III 
Q1(t) = y(t)V P %D plasmapool IV 
%D/L plasmaconc. V 
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According to the methods as outlined in refs. 19 and 23 the constants in the 
equations I - V were calculated: Cumulative uptake in the REP :(Q2) was 
calculated by numerical solution of equation II for the time interval from 0 
to 360 min., in 1 min. steps, as follows: 
Qz(tn) = Qz(tn-1) + k21Q1(tn-1)- (k12 + koz)Qz(tn-1) 
=kz1Q1(tn-1)+(l- k12- ko2)Qz(tn-i) 
Attn== 0 : Q2(to) =0 and Q1(to) = 100 
therefore at 1 min (n=l) 
Qz(h) =k21Q1(tn-1) = kz1.100 
%D VI 
%D 
%D 
Subsequently Qz(tn) is calculated for each minute from 2 to 360 min by solving 
VI, using the previously found Q2(tn-1); and using Q1(tn-1) after solving of IV 
and V. 
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CHAPTERS 
Summary 
After the discovery ofT3 in 1952, it was already assumed that this iodothyronine 
represents the metabolically active form of thyroid hormone, while T4, which 
is exclusively synthesized in the thyroid, must be regarded as a prohormone. 
Although conversion ofT 4 to T 3 in peripheral tissues was already demonstrated 
in 1954, the observation (1970) that L-thyroxine substituted athyreotic persons 
showed normal serum T3 levels, really focussed the attention to the peripheral 
activation of thyroid hormone. Apart from the question in which tissues this 
activating 5' -deiodination was accomplished, it was soon realized that T 3 and 
reverse T3 (a biologically inactive analogue of T3, formed by 5-deiodination 
of T4) in serum were not always present in a fixed ratio, but that reciproke 
changes in serum levels of these hormones could be detected in several conditions. 
Thus, predictable, reproducible and reversible alterations in serum levels of 
T3 and reverse T3 (rT3) could be induced by several situations of which caloric 
restriction, non-thyroidal illness, treatment with propranolol, dexamethasone 
and propylthiouracil and administration of cholecystographic agents as ipodate, 
are best known. In these conditions serum levels of T 3 are decreased, those 
of rT3 are increased, while serum T4 concentrations do not change greatly. 
These changes in serum thyroid hormone levels are known as the low T 3 
syndrome. 
CHAPTER 1 reviews some important aspects of peripheral thyroid hormone 
metabolism in relation to the generation of the low T 3 syndrome. 
Kinetic studies revealed that the decrease in serum T3 level and increase 
in serum rT3 concentration result from a decreased T3- production rate and 
rT3 metabolic clearance rate, while rT3 generation and T3 degradation are 
unaltered. These findings were explained by inhibition of 5'-deiodination of 
T4 and rT3, which was supported by in vitro experiments with rat liver 5'-
deiodinase. 
Two important observations, however, challenged this theory as the; sole 
explanation for the generation of the low T3 syndrome. Firstly, it was shown 
that in perfused livers of fasted rats, a decreased hepatic T4 uptake equid be 
demonstrated while the T 4 to T 3 conversion rate was unaltered. It was also 
shown that inhibition of deiodination per se by propy,lthiouracil did not influence 
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T4 uptake by the perfused liver. Subsequently, others and work from our 
laboratory independently showed the existence of an energy dependent uptake 
mechanism for T 4, T 3 and rT 3 in rat hepatocytes. It was further shown from 
our work that T 4 and rT 3 entered the cell by a common pathway that is different 
from that of T3. The activity of these two pathways appeared to be ATP-
dependent. It seemed feasable that changes in transport through these uptake 
systems could also (apart from any possible change in deiodination) cause 
the descripted changes in serum iodothyronines, as seen in the low T3 syndrome. 
The aim of this thesis was to assess to what extent changes in these two 
mechanisms i.e. 5' -deiodination and transmembraneous transport of iodothy-
ronines, could be causative in the low T 3 syndrome. 
Essentially, three conditions were examined: caloric deprivation, oral ad-
ministration of d-propranolol and a state of (transient) ATP- depletion of the 
liver, induced by fructose infusion. These studies were analyzed according to 
a three compartmental model of distribution and metabolism of thyroid 
hormone. 
CHAPTER 2 deals with the effects of caloric deprivation on tissue uptake 
of thyroid hormone. Ten obese subjects were studied before and after seven 
days on a 240 kcal diet. During caloric deprivation serum free T4levels increased 
by 25%, while total T4 levels did not change. In spite of an increased free 
T 4 serum level, hormone transport into the tissues was markedly decreased, 
indicating an inhibition of transmembraneous transport. T 4 production rate 
was decreased, presumably due to the raised serum free T 4 concentration, 
resulting in a diminished TSH secretion. Because the metabolic clearance rate 
decreased proportionately, no change was observed in total T4levels. Although 
less pronounced in comparison with T4, diminished T3 transport into the tissues 
could also be demonstrated. This is in concert with in vitro observations in 
rat hepatocytes in primary culture, where transmembraneous transport of T 3 
appeared to be less sensitive to inhibitory influences than T 4· Although an 
additional role of a decreased 5'-deiodinase activity could not be excluded, 
the results of the experiments, described in this chapter, point to an inhibition 
of transmembraneous transport of T 4 during caloric deprivation as at least 
an important factor contributing to low T 3 production and low T 3 serum levels, 
due to less T4 availability in tissues. 
In CHAPTER 3 results are described of tracer T 4, T 3 and rT 3 kinetic studies 
in six normal male L-thyroxine substituted subjects before and during oral 
d-propranolol treatment. D-propranolol induced a decrease in T4 plasma 
appearance rate by 16%, presumably due to reduced intestinal absorption of 
L-thyroxine, although a d-propranolol effect on thyroidal secretion of T4 not 
suppressed by exogenous T4, cannot be excluded. A reduction of 26% in the 
T4 metabolic clearance rate only partially countereffected by a 16% decrease 
in plasma appearance rate, explains an increase in both total T 4 and free T 4 
serum levels. Inhibition of transport of thyroxine into the tissues could not 
be demonstrated. The decreased T3 production could, thus, not be attributed 
80 
to a diminished thyroxine availability for 5'-deiodination. In addition, it could 
also be shown that d-propranolol did not inhibit the passage of T 3 and rT 3 
through the cell-membrane. From the experiments described in chapter 3, it 
is concluded that the d- propranolol induced changes in thyroid hormone 
metabolism, resulting in a low T3 syndrome, are due to inhibition of thyroid 
hormone deiodination, which is in contrast to the low T 3 syndrome during 
caloric deprivation (chapter 2). 
CHAPTER 4 shows early serum T 4 tracer disappearance curves and computed 
T4 uptake by the rapidly equilibrating pool, which is believed to be largely; 
comprised by the liver. In concert with the observations in chapter 2, caloric 
deprivation results in a slower clearance of tracer T 4 from the ·blood in 
concomitance with a decrease in T4 uptake by the rapidly equilibrating pool 
( liver). In chapter 3 it was shown that d-propranolol did not interfere with 
passage of iodothyronines through the cell-membrane. In agreement with these 
findings is an unalterd T4 tracer disappearance from the blood and an unchanged 
computed T 4 uptake by the rapidly equilibrating pool during d-propranolol 
administration. 
Because transmembraneous transport of iodothyronines in rat hepatocytes 
in primary culture was shown to be A TP-dependent, an intravenous fructo!!e 
load was given to four persons. This procedure results in a prompt ATP-depletion 
of the liver. In accordance with this effect, a temporarily increase in serum 
uric acid and lactate was noted. Fructose loading resulted in a slower 
disappearance of thyroxine from the blood in conjunction with a decreased 
computed T 4- uptake by the rapidly equilibrating pool. These findings support 
an A TP-dependency of the transport system for iodothyronines in vivo. 
In conclusion: in this thesis, experiments are described from which it can be 
concluded that alterations in serum thyroid hormones as observed in the low 
T 3 syndrome, can originate by both inhibition of 5' -deiodination and inhibition 
of transmembraneous transport of iodothyronines. The low T 3 syndrome during 
d-propranolol administration results from the former mechanism, while the 
latter mechanism is operating during caloric restriction. Furthermore, data are 
presented in support of an in vivo A TP-dependency of the transmembraneous 
transport system of iodothyronines. 
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Samenvatting 
Na de ontdekking van T3 in 1952 vermoedde men al spoedig dat de metabole 
activiteit van het schildklierhormqon via deze jodothyronine tot stand kwam, 
terwijl T4, dat uitsluitend in de schildklier wordt gemaakt, beschouwd moest 
worden als een prohormoon. Hoewel al in 1954 was aangetoond, dat in perifere 
weefsels T4 kon worden omgezet in T3, richtte men pas zijn voile aandacht 
op deze 'perifere activatie van schildklierhormoon, toen bleek (1970) dat 
athyreote personen die met L-thyroxine werden gesubstitueerd·, normale T:i 
spiegels in hun bloed hadden. Naast de vraag in welke weefsels in vivo deze 
activerende 5'- dejodering plaats vond, bleek dat T 3 en reverse T 3 ( een biologisch 
inactieve triidothyronine, gevormd door 5-dejodering van T4) niet in een vaste 
verhouding in het bloed voorkwamen, maar dat onder verschillende omstan-
digheden reciproke veranderingen in de bloedspiegels van deze hormonen 
werden gevonden. Deze veranderingen bleken voorspelbaar, reproduceerbaar 
en reversibel. De bekenste situaties waarin genoemde veranderingen in bloed-
spiegels van T 3 en reverse T 3 (rT 3) optreden, zijn: vasten, ziekte in het algemeen 
bij euthyreote personen, behandeling met propranolol, dexamethason en pro-
pylthiouracil en toedienen van rontgencontrastmiddelen voor cholecystografie, 
zoals ipodate. Onder deze omstandigheden is de bloedspiegel van T 3 verlaagd,die 
van rT 3 verhoogd, terwijl de concentratie van T 4 in het bloed niet sterk verandert. 
Deze veranderingen in de concentraties van T 4, T 3 en rT 3 staan bekend als 
het laag T 3 syndroom. 
HOOFDSTUK 1 geeft een overzicht van belangrijke aspecten van het perifere 
metabolisme van schildklierhormoon met betrekking tot het ontstaan van het 
laag T 3 syndroom. 
Kinetische studies toonden aan dat de daling in de bloedspiegel van T 3 werd 
veroorzaakt door een verminderde aanmaak van dit hormoon. De stijging in 
de bloedspiegel van rT 3 kon verklaard worden door een verminderde afbraak. 
De afbraak van T 3 en de aanmaak van rT 3 bleken onveranderd. Deze bevindingen 
werden verklaard door aan te nemen dat de 5'-dejodering van T4 en rT3 was 
afgenomen. In vitro experimenten met 5'-dejodase uit rattelever ondersteunden 
deze theorie. 
Twee belangrijke waarnemingen echter, zorgd~n er voor dat er twijfel ontstond 
dat remming van de 5'-dejodering de enige verklaring vormde voor het ontstaan 
van het laag T 3 syndroom. Allereerst bleek dat levers van gevaste ratten bij 
perfunderen met T4, minder van dit hormoon opnamen dan levers van controle-
dieren. Het percentage van het opgenomen T4 dat in T3 werd omgezet, was 
in beide groepen identiek. Tevens toonde men aan dat remming van de dejodering 
sec door propylthiouracil geen invloed had op de opname van T4 tijdens de 
perfusie. Vervolgens werd in verschillende laboratoria, onafhankelijk van elkaar, 
het bestaan van een energie-afhankelijk opname systeem voor jodothyronines 
aangetoond. Zo konden Krenning en Docter in ons laboratorium in ratte-
hepatocyten in pri~aire kweek, een actief energie-afhankelijk opnamesysteem 
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aantonen, waarbij T 4 en rT 3 de eel binnen worden gevoerd via eenzelfde pad, 
terwijl T3 via een afzonderlijk opnamemechanisme de eel binnenkomt. 
De activiteit van deze twee opname systemen bleek A TP-afhankelijk. Het 
bleek mogelijk om,, met enige aannames, via veranderingen in dit transport-
systeem, eveneens een verklaring te geven voor de veranderingen in schild-
klierhormoon, optredend tijdens het laag T 3 syndroom. 
Het doel van dit proefschrift was vast te stellen in hoeverre veranderingen 
in deze twee mechanismen, namelijk 5'-dejodering en transport van jodothy-
ronines door de celmembraan, bijdragen in het ontstaan van het laag T 3 
syndroom. 
Drie situaties werden onderzocht: vasten, orale toediening van d- propranolol 
en een toestand waarbij een passagere ATP-depletie van de lever optreedt ten 
gevolge van intraveneuze toediening van fructose. De resultaten van de 
experimenten werden geanalyseerd volgens een systeem waarbij de verdeling 
en het metabolisme van schildklierhormoon werden benaderd via een drie-
compartimenten model. 
In HOOFDSTUK 2 wordt het effect van vasten op de opname van 
schildklierhormoon door de weefsels besproken. Tien adipeuze personen werden 
bestudeerd voor en na een periode van zeven dagen waarbij zij een dieet kregen 
bestaande uit 240 Kcal. Tijdens deze periode met beperkte toevoer van calorieen 
steeg de vrije T4 concentratie met 25% ten opzichte van de controleperiode. 
De totale T4 concentratie veranderde niet. Ondanks de stijging van de vrije 
T4 concentratie nam het transport van thyroxine naar de weefsels aanzienlijk 
af, hetgeen wijst op een remming van transport van T4 door de celmembraan. 
De aanmaak van T4 was verminderd, waarschijnlijk ten gevolge van een 
verminderde TSH secretie, veroorzaakt door de stijging van de vrije T4 
concentratie. Omdat de metabole klaring van T4 evenredig was afgenomen, 
werd geen veiandering in de totale T4 concentratie waargenomen. Het transport 
van T 3 naar de weefsels bleek eveneens verminderd, hoewel minder uitgesproken 
dan bij T4. Dit is in civereenstemming met de in vitro bevindingen in rat-
tehepatocyten waar bet transport van T3 door de celmembraan minder gevoelig 
bleek voor remmende invloeden. Hoewel het niet is uitgesloten dat een 
verminderde 5' -dejodering eveneens een bijdrage Ievert aan de verminderde 
T3 productie, geven de resultaten uit dit hoofdstuk duidelijk aan, dat remming 
van transport van thyroxine door de celmembraan, op zijn minst een belangrijke 
factor vormt in de verminderde T 3 aanmaak tijdens vasten. 
In HOOFDSTUK 3 worden de resultaten beschreven van 'kinetische studies 
met radioactief gemerkt ,T4, T3 en rT3 bij zes normale, mannelijke personen, 
gesubstitueerd met L-thyroxine, voor en ' tijdens orale toediening van d-
propranolol. Tijdens d-propranolol toediening nam de plasma appearance rate 
van T4 met 16% af, waarschijnlijk ten gevolge van een verminderde resorptie 
van thyroxine in de darm, hoewel een effect van d-propranolol op de secretie 
van T 4 door de schildklier, die mogelijk niet geheel was onderdrukt door exogeen 
toegediend- T 4, niet geheel kon worden uitgesloten. De toename van zowel de 
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concentratie van het vrije T4 als het totale T4 gehalte, kan worden verklaard, 
doordat de afname van de metabole klaring van T4 met 26% slechts ten dele 
wordt gecompenseerd door een daling in de plasma appearance rate van 16%. 
Ben remming van het transport van thyroxine naar de weefsels kon niet worden 
aangetoond. De verminderde T 3 productie kon dus niet worden toegescbreven 
aan een verminderde bescbikbaarheid van T4 voor 5'-dejodering. Zo bleek ook 
dat de passage van T 3 en rT 3 door de celmembraan niet was geremd. Uit de 
resultaten beschreven in hoofdstuk 3, kan worden geconcludeerd dat de 
veranderingen in het metabolisme van schildklierbormoon tijdens het laag T 3 
syndroom veroorzaakt door d-propranolol, ontstaan door een remming van 
dejodering van scbildklierhormoon en niet, zoals bij vasten, door remming 
van het transport van schildklierhormoon door de celmembraan (hoofdstuk 
2). 
IIi HOOFDSTUK 4 worden curves getoond die de verdwijning van radioactief 
gemerkt T 4 uit het serum weergeven in de tijd. Tevens wordt de berekende 
opname van T 4 door het snel equilibrerende compartiment in de tijd aangegeven 
in dezelfde situaties. Men neemt aan dat bet snel equilibrerende compartiment 
voornamelijk uit de lever bestaat. In overeenstemming met de bevindingen 
uit hoofdstuk 2, blijkt radioactief gemerkt T4 langzamer uit het bloed te 
verdwijnen tijdens vasten. Tegelijkertijd blijkt bet snel equilibrerende compar-
timent (lever) minder T4 op de te nemen. In boofdstuk 3 bleek dat d- propranolol 
de passage van jodothyronines door de celmembraan niet belemmert. Volgens 
verwacbting bleek de verdwijning van T4 uit bet bloed en de opname van dit 
hormoon door bet snel equilibrerende compartiment, tijdens d-propranolol 
toediening onveranderd ten opzichte van de controle periode. · 
Omdat in rattebepatocyten was gebleken, dat het transport systeem voor 
jodothyronines ATP-afhankelijk was, kregen vier personen intraveneus fructose 
toegediend. Dit veroorzaakt een snelle daling van ATP in de lever. Deze tijdelijk 
fructose toediening resulteerde in een langzamere verdwijning van T 4 uit het 
bloed in combinatie met een verminderde opname van thyroxine door het snel 
equilibrerende compartiment. Deze resultaten steunen een A TP-afhankelijkheid 
van genoemd transport systeem voor jodothyronines. 
Samenvattend kan uit de in dit proefschrift beschreven experimenten worden 
geconcludeerd, dat veranderingen in de bloedspiegels van schildklierhormonen 
als waargenomen tijdens het laag T 3 syndroom, kunnen ontstaan door zowel 
remming van de 5' -dejodering als door remming van transmembraneus transport 
van jodothyronines. Ret laag T 3 syndroom tijdens d-propranolol ontstaat via 
remming van de 5'- dejodering, vasten veroorzaakt een remming van transport 
van schildklierhormoon door de celmembraan. Tevens worden gegevens ge-
presenteerd die een in vivo A TP-afhankelijkheid van dit transport systeem 
ondersteunen. 
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NAWOORD 
Velen hebben bijgedragen aan de totstandkoming van dit proefschrift. Aan 
hen allen ben ik dank verschuldigd. 
Met name denk ik met dankbaarheid terug aan mijn vader, die zowel tijdens 
mijn studie en opleiding tot internist als bij mijn promotie- onderzoek, voor 
mij een grote stimulans is geweest. Aan hem draag ik dit proefschrift op. 
Toen ik in 1979 mijn opleiding tot internist aanving, wist Eric Krenning, in 
die periode mijn chef de clinique, mij op zijn eigen, enthousiaste wijze te 
doordringen van de vele boeiende aspecten van bet metabolisme van schild-
klierhormoon. Hij introduceerde mij in de schildkliergroep en is gedurende 
het gehele onderzoek voor mij een grote steun geweest. Door hem kwam ik 
in een vroege fase van mijn opleiding in nauw contact met J org Hennemann, 
die behalve als opleider en promotor, in deze periode, maar zeker ook daarna, 
een grote invloed op mij heeft gehad. Met dankbaarheid denk ik terug aan 
de vele gesprekken die ik met hem heb gevoerd, waarbij tal van andere 
onderwerpen dan in dit proefschrift genoemd, aan de orde kwamen. Deze 
gesprekken hebben veel voor mij betekend. 
Roel Docter wil ik danken voor zijn grote inzet op alle terreinen waar het 
onderzoek zich afspeelde. Zonder hem was dit proefschrift niet tot stand 
gekomen. Ik dank hem met name voor zijn geduldige opstelling tegenover 
mijn gebrekkig wiskundig inzicht. 
Vee I dank ben ik ook verschuldigd aan Hans van To or, die verreweg het grootste 
deel van alle hormoonbepalingen verrichtte. Steeds weer was hij bereid om 
nieuwe wendingen in het onderzoek logistiek op voortreffelijke wijze te steunen. 
Veel kennis heb ik verworven tijdens de wekelijkse schildklierbesprekingen. 
De verschillende onderzoekslijnen binnen de schildkliergroep kwamen hier 
uitgebreid aan de orde, waardoor ik veel heb kunnen Ieren in de gesprekken 
met Theo Visser, Marten Otten en Jan Mol. 
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Met veel genoegen denk ik terug aan de hulp die ik gekregen heb op de 
balansafdeling. Hiervoor wil ik met name Joke van Vuure, Marijke Hengeveld 
en Cootje van Aller bedanken. 
Tevens wil ik ook deze gelegenheid aangrijpen om Peter Kooij, Willem Bakker, 
Eef Harmsen, Peter de Tombe en Fred Bonthuis mijn dank uit te brengen 
voor hun inzet, met name in de beginperiode van het onderzoek. 
Joke Nijsse verzorgde op uitstekende wijze de uiteindelijke invoer van het 
manuscript in de tekstverwerker. 
Tot slot spreek ik mijn dank uit aan alle proefpersonen die hun medewerking 
verleend hebben aan dit onderzoek. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd op 8 november 1952 te Rotterdam geboren. 
Na het behalen van het gymnasium-beta diploma in 1971 (Sint Franciscus 
College, Rotterdam) studeerde hij geneeskunde aan de Medische Faculteit 
Rotterdam, alwaar in februari 1978 het artsexamen werd afgelegd. Aansluitend 
vervulde hij zijn militaire dienstplicht bij de Koninklijke Landmacht. In 1979 
ving hij zijn opleiding tot internist aan op de afdeling Inwendige Geneeskunde 
III van het Academisch Ziekenhuis Rotterdam - Dijkzigt (Hoofd: Prof. Dr. 
J.C. Birkenhager). Op deze afdeling werd dit proefschrift bewerkt onder leiding 
van Prof. Dr. G. Hennemann. Op 1 januari 1985 volgde inschrijving in het 
specialistenregister. Sedert 1 april 1985 is hij als internist verbonden aan het 
Sint J ozef Ziekenhuis te Gouda. 
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